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Abstract
The development of cancer from a population of precancerous cells is a rapid evolu-
tionary process. During progression, cells evolve several new traits for survive and
proliferation via a few key ‘driver’ mutations. However, these few driver alterations
reside in a cancer genome alongside tens of thousands of additional ‘passenger’ muta-
tions. Passengers are widely believed to have no role in cancer, yet many passengers
fall within functional genomic elements that may have potentially deleterious eﬀects
on the cancer cells. Here we investigate the potential of moderately deleterious pas-
sengers to accumulate and alter neoplastic progression.
Evolutionary simulations suggest that moderately-deleterious passengers accumu-
late during progression and largely evade natural selection. Accumulation is possible
because of cancer’s unique evolutionary constraints: an initially small population size,
an elevated mutation rate, and a need to acquire several driver mutations within a
short evolutionary timeframe. Cancer dynamics can be theoretically understood as
a tug-of-war between rare, strongly-beneﬁcial drives and frequent mildly-deleterious
passengers. In this formalism, passengers present a barrier to cancer progression de-
scribable by a critical population size, below which most lesions fail to progress, and
a critical mutation rate, above which cancers collapse. In essence, cancer progression
can be subverted by its own unique evolutionary constraints.
The collective burden of passengers explain several oncological phenomena that
are diﬃcult to explain otherwise. Genomics data conﬁrms that many passengers are
likely damaging and have largely evaded negative selection, while age-incidence curves
and the distribution of mutation totals suggests that drivers and passengers exhibit
competing eﬀects. These data also provide estimates of the strength of drivers and
passengers.
Finally, we use our model to explore cancer treatments. We identify two broad
regimes of adaptive evolutionary dynamics and use these regimes to understand out-
comes from various treatment strategies. Our theory explains previously paradox-
ical treatment outcomes and suggest that passengers could serve as a biomarker of
response to mutagenic therapies. Deleterious passengers are targetable by either (i)
increasing the mutation rate or (ii) exacerbating their deleterious eﬀects. Our results
suggest a unique framework for understanding cancer progression as a balance be-
tween driver and passenger mutations.
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1
Introduction
Cancer is a disease of clonal evolution in the body84. Somatic cells divide and die
hundreds or thousands of times during a human lifetime. They exist within a niche of
the body, often termed a microenvironment in cancer literature, that requires these
cells to respond to stimuli. Finally, somatic cells can acquire their own somatic muta-
tions that often confer new phenotypic traits to the cells, which may then be selected
for or against by the cell’s microenvironment. For these reasons, somatic tissues can
1evolve. They change morphology and adapt to their environment and, as such, can
only be understood ‘in the Light of Evolution’84,37,56,8,58,76,7,104,88.
The early, small populations of somatic cells that may eventually evolve into can-
cer, or lesions, were ﬁrst identiﬁed by their two most salient phenotypes: an abnor-
mally fast rate of cell division, and an abnormally large degree of variability in cell
morphology122. This ﬁrst phenotype (enhanced cell division) is an irony of evolu-
tion: enhanced cell division is highly advantageous to individual somatic cells in a
microenvironment, yet highly disadvantageous (often lethal) to the organism as a
whole. Thus, mutations that increase cell’s rate of proliferation are selected for in so-
matic tissue, yet selected against in the organism’s germ-line29. However, the second
most salient feature of lesions, increased phenotypic variability, is equally important
for their evolution into cancer. Indeed, without a continual source of new phenotypic
variation, precancerous cells will never sample the other carcinogeneic traits necessary
for progression.
Precancerous evolution, or cancer progression, is an example of a ‘rapidly adapt-
ing population’: cancers develop as many as ten new traits54, exhibit a high mutation
rate54,7,72, and rapidly change in population size30. Developing so many new traits in
an evolutionarily-short time period of approximately 10,000 cell divisions is only pos-
sible because new traits arrive at an accelerated pace, which is only possible because
precancerous cells’s exhibit a high mutation rate7.
While many populations evolve new traits via a gradual accumulation of changes,
some, like cancer, adapt very rapidly. Other examples include viral adaptation dur-
ing infection60; the emergence of antibiotic resistance128; and artiﬁcial selection in
biotechnology124. Rapid adaptation in all these circumstances is characterized by
three key features: (i) the availability of strongly advantageous traits through rare
2mutations, (ii) an elevated mutation rate91,60, and (iii) a dynamic population size18.
Because traditional theories of gradual adaptation are not applicable under these con-
ditions, new approaches are needed.
Recent advances in sequencing and genotyping of cancer tissues at a genome level
have found that individual cancers contain tens of thousands of somatic alterations101,102,11,111,
which can be explained by cancer’s enhanced mutation rate and enhanced rate of cell
division. These alterations arise in many forms, such as single-nucleotide substitu-
tions, insertions, deletions, rearrangements, Loss Of Heterozygosity (LOH) events,
copy-number alterations, and whole-chromosome duplications/deletions101; epigenetic
alterations107; and inheritable changes in cell state. Progression is driven by only a
handful (2-15) of cancer’s myriad of mutations71 and chromosomal abnormalities127.
From an evolutionary perspective, drivers confer advantageous phenotypes to neo-
plastic cells (i.e., phenotypes that allow cells in the population to proliferate further).
This property is inferred by their eﬀect on cancer-related pathways; frequent occur-
rence at the same genes, loci, or pathways in diﬀerent patients11,111,85; and by the
structure of cancer incidence rates52. Drivers arise in cancer-related genes (oncogenes
and tumor suppressors) and are beneﬁcial to cancer cells because their phenotypes
either increase the cell proliferation rate, eliminate brakes on proliferation, facilitate
uncontrolled proliferation or other hallmarks of cancer54. Because the arrival of driver
mutations is so critical to cancer progression, their discovery has been the primary
goal of genome-wide cancer sequencing39.
In contrast, the overwhelming majority of mutation events in cancer are believed
to have non-signiﬁcant phenotypes and are called passenger alterations or simply pas-
sengers (table 1.1 on the following page). Little attention has been paid to passen-
gers111. These alterations are assumed to be phenotypically neutral in cancer cells be-
3Table1.1: Averagenumberofdriverandpassengermutationsbytumortype. Thetotalnumberofidentiﬁed
SomaticNonsynonymousMutations(SNMs)andSomaticCopyNumberAlterations(SCNAs)forvarioustumor-
normalpairedsequencesfromvarioustissuesoforigin: 100breast
115,183lung
28,159ColonwithoutMicro-
satelliteINstability(MIN ),64ColonwithMicro-SatelliteInstability(MIN+)
21,and121melanomas
10.
NSM NSM SCNA SCNA
Cancer Drivers Passengers Drivers Passengers
breast 1.7 70.8 1.0 34.6
lung 2.3 348.6 8.4 89.5
colon, MIN  8.8 114.0 14.1 583.5
colon, MIN  28.8 489.0 12.7 235.1
melanoma 7.0 379.6 12.6 324.7
all 9.1 272.8 8.8 258.9
Max 28.8 489.0 14.1 583.5
Min 1.7 70.8 1.0 34.6
cause they are non-recurrent and are dispersed across a cancer genome39,22; however,
their phenotype has never been systematically tested. If passengers arise as random
alterations, then many could be deleterious to cancer cells90,27,40, potentially via pro-
teotoxic stress93,41,108, direct loss of function14,79, or immune provocation3,120 among
other possible mechanisms.
Although highly deleterious passengers are expected to be weeded out by negative
selection7, moderately deleterious passengers can evade negative selection and accu-
mulate by mutation-selection balance, ratcheting, or similar mechanisms studied in
population genetics44. Protein-coding passengers may individually exert small eﬀects,
but because cancer genomes contain hundreds to thousands of passengers, they may
collectively be signiﬁcant enough to alter the course of cancer progression.
While the role of deleterious mutations in cancer is largely unknown, their eﬀects
on natural populations has been extensively studied in genetics77,57,48. The accumu-
lation of deleterious mutations can cause population extinction by a process known as
4Muller’s ratchet or mutational meltdown77,92. How this applies to rapidly adapting
populations with a varying size, with highly advantageous mutations, and speciﬁcally
to cancer, remains unknown.
Rapidly adapting populations face a double bind: they must quickly acquire these,
often exceedingly rare, adaptive mutations, yet also avoid mutational meltdown. As
a result, adaptive processes frequently fail. Indeed, less than 0.1% of species on earth
have adapted fast enough to avoid extinction82 and, similarly, only  0.1% of precan-
cerous lesions ever advance to cancer98. Cancer therapies may be able to exploit this
pitfall of evolution (extinction) and cancer’s distinctive method of rapid adaptation to
avoid extinction67.
Here we investigate the possible role of deleterious passenger alterations in cancer
progression and examine their potential as an unexploited therapeutic target. First,
we develop an evolutionary model of rapid adaptation, where (i) population size can
change freely, (ii) individual’s experience an elevated mutation rate that, (iii) can gen-
erate both advantageous driver mutations and (iv)deleterious passenger mutations.
We ﬁnd that moderately deleterious passengers can arise alongside drivers in this
model, and evade purifying selection. The accumulation of passengers alters the dy-
namics of cancer progression and may explain several clinical phenomena, such as
slow progression, long periods of dormancy, the prevalence of small subclinical can-
cers, spontaneous regression, and heterogeneity in growth rates. These phenomenon
cannot be easily explained without considering deleterious passengers. Unlike the cur-
rent driver-centric paradigm of cancer progression, our analyses demonstrate that pro-
gression depends on drivers overcoming passengers.
Mutational meltdown is possible and common in evolving precancerous popula-
tions. In fact, we observed a tug-of-war between beneﬁcial drivers and deleterious pas-
5sengers that creates two major regimes of population dynamics: an adaptive regime,
where the probability of adaptation (cancer) is high; and a non-adaptive regime,
where adaptation (cancer) is exceedingly rare. These regimes are separated by an ef-
fective barrier, which makes cancer progression an unlikely event.
We then tested the model’s predictions by analyzing somatic mutations sequenced
in cancers. This analysis shows that, in agreement with the model, individual pas-
sengers are likely to be damaging to cells and have largely evaded negative selection.
Drivers, in contrast, exhibit signatures of highly non-neutral phenotypes. Our model
is consistent with cancer genomic patterns and age-incidence data, oﬀers a new inter-
pretation of cancer treatment strategies, and explains a previously paradoxical rela-
tionship between cancer mutation rates and clinical outcomes. Most importantly, it
suggests that deleterious passengers oﬀer a new, unexploited avenue of cancer ther-
apy.
Thus, we used our model to explore two possible therapeutic approaches that tar-
get passengers’ collective phenotype and ﬁnd that increasing either the mutation rate
or the deleterious eﬀect of passengers leads to cancer meltdown. The latter therapy
may be possible by targeting pathways that buﬀer the eﬀects of mutations, e.g., un-
folded protein response (UPR) pathways.
Finally, we present and discuss clinical and biological evidence that supports an
important role of passenger alterations in cancer. Our analysis further explains how
asexual populations such as cancer rapidly evolve new traits while occasionally avoid-
ing mutational meltdown.
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An evolutionary model of cancer
progression with deleterious passengers
In this chapter, I present a very simple model of cancer progression incorporating
deleterious passengers. While the model is simple, the chapter is rather slow and
methodical because I want to entertain all reasonable models of cancer progression
before settling on the one that constitutes my primary focus. This entails review-
7ing some of the more technical properties of cancer and it corresponding models. It
also requires discussing circumstances where models are equivalent to one another;
and then the circumstances that are most relevant to cancer progression, which varies
from tumor to tumor. So although this chapter may seem dry, I actually believe it
encapsulates the most challenging aspect of science: literature review at a technical
level, analytical deconstruction of theories, and developing a rigorous intuition for the
strengths and limitations of existing models and paradigms.
Existing evolutionary models of cancer progression have several limitations. Many
models have considered a population of a constant or externally controlled size113,8,
which does not depend on the absolute ﬁtness of cells. Other models study exponen-
tially growing cancer populations52,8,56, whereas logistic-like behavior has been ob-
served in cancer70. Most importantly, the vast majority of cancer models neglect the
eﬀects of passenger alterations. In the last section of this chapter, I discuss two publi-
cations that do brieﬂy consider deleterious passengers in cancer.
2.1 Cancer as a birth and death process
We model cancer at the cellular level. Cells can divide, potentially acquiring muta-
tions, and die. Generally, the birth and death rates of a cell depend on the eﬀect of
accumulated drivers and passengers, and the environment. Assuming that all drivers/passengers
possess equal ﬁtness advantage/disadvantage, the birth and death rates B nd;np;N 
and D nd;np;N  of each cell depend on the number of drivers nd, the number of pas-
sengers np, and the total hyperplasia or population size N. In chapter 3 on page 22,
we model drivers & passengers of variable eﬀect size. Hence, we can model these com-
peting birth and death rates using a ﬁrst-order Gillespie Algorithm, speciﬁcally the
8Next Reaction43. Each cell within the population is represented as a separate ‘chemi-
cal species’ or reactant in the Gillespie algorithm. Cells are then deﬁned by their state
 nd;np  in this simplest algorithm, and by a generalized genome vector in more so-
phisticated implementations.
Population size changes with the birth and death of individual cells (ﬁgure 2.1 on
the following page). Driver mutations increase population size by either increasing
the birth rate (e.g., an activating mutation in KRAS) or by decreasing the death rate
(e.g., a TP   knockout that diminishes contact inhibition62 and apoptosis). Though
speciﬁc drivers and passengers will have diﬀering eﬀects on the birth and death rates,
below we will demonstrate that aggregating the eﬀects of mutations into the birth
rate, and placing the eﬀects of population size into the death rate, does not alter pop-
ulation dynamics from models where mutational eﬀects are split between the two (ﬁg-
ure 3.5 on page 30). Thus, we use:
B nd;np   
    sd
    sp
D N   
N
N  (2.1)
(2.2)
where sd is the ﬁtness advantage (selection coeﬃcient) of a driver, sp is the ﬁtness
disadvantage conferred by a passenger, and N  is the initial equilibrium population
size—reﬂecting the eﬀects of the tumor microenvironment. This model assumes ‘mul-
tiplicative’ epistasis and is mathematically equivalent to B nd;np         sd nd    
s′
p np when s′
p   sp=     sp . In section 3.3 on page 36, we discuss the eﬀects of al-
ternative models of epistasis, speciﬁcally an ‘additive’ epistasis model and a ‘two-hit’
model of carcinogenesis. Both models exhibit similar behavior to this original model.
For our initial, mathematically-tractable model, the death rate increases linearly
9Driver Muta on Cell Division Event Death Event Passenger
sp
sd
Td
Tp
B(d,p) D(N) µTd µTp
+sd
-sp
Muta on
Figure2.1: Amodelofcancerprogressionwithdriversandpassengers. Ourevolutionarymodel: individual
cancercellscanstochasticallydivide(potentiallyacquiringnewdriversorpassengers)anddie. Anewdriverin-
creasesthebirthratebysd,whereasapassengerdecreasesthebirthratebysp (equation(2.1)ontheprevious
page). (LowerLeft)Driversariserarely(reﬂectedbyasmallTd),buthavealargeeffectsizesd,whilepassengers
arecommon(largeTp),buthavesmallindividualeffectssp. (LowerRight)Aconceptionofapopulationstochas-
ticallydividinganddying. Whenadriverarisesinthepopulation,itscloneexpandsandcarrieswithitdeleterious
passengers.
10with population size (similar to previous neoplastic58 and ecological33 models). How-
ever, in later sections, when discussing large tumors (grown to     cells), we let D N   
Log     N=N  . For small N=N , during early carcinogenesis, this reduces to the lin-
ear model above, but for large N=N  this recapitulates Gompertzian dynamics ob-
served experimentally for large tumors50. The death rate’s dependence on population
size is a coarse approximation of many size-dependent factors that tumors must over-
come as they expand via additional drivers: contact inhibition, competition between
cells for space and resources (e.g., due to a limited crypt size), homeostatic pres-
sure, hypoxia, angiogenesis, limited paracrine signaling, and immune/inﬂammatory
responses to larger tumors3.
We do not track individual cell’s position in space. Hence, in every model we con-
sider here, the environment must be homogenous and we must ignore the spatial
structure of cancer. Previous studies of asexual populations suggest that ignoring spa-
tial structure will (i) underestimate the time for beneﬁcial drivers to sweep through
the population and hence the degree of clonal interference, and (ii) overestimate the
eﬀective strength of selection, which only acts at the geographic boundary between
clones64,65. Hence, models considering spatial structure should ﬁnd that more pas-
sengers ﬁxate relative to those that do not, thereby strengthening the conclusions of
our model. Nevertheless the eﬀects of spatial constraints have been largely left to fu-
ture studies and is an area of particular interest to us—especially because it generally
increases the amount of genetic diversity in a population.
During division, cells can also acquire driver and passenger mutations. The num-
ber of acquired driver mutations during division ∆d and the number of acquired pas-
senger mutations during division ∆p are Poisson-distributed pseudorandom variables
with means d and p, respectively; Thus, for passengers: P ∆p   k p   
 p ke p
k  .
11These driver and passenger mutation rates are a product of the overall per-locus mu-
tation rate  multiplied by the respective targeted sizes of drivers Td and passengers
Tp (i.e. number of accessible driver/passenger loci). Hence, d   Td and p   Tp.
In this model, mutations arise at a rate proportional to generation time, rather
than absolute time. Our choice, therefore, reﬂects our belief that most mutational
processes occur in a cell division-dependent manner (e.g. mutations in cell-cycle check-
points like p53), rather than independent of cell division. Certainly, some mutational
processes occur independent of cell division. However, because the generation time in
precancerous cells accelerates only mildly over the course of progression, introducing
mutations at an absolute rate would not signiﬁcantly alter dynamics. Also, mutations
that do not arise as a direct result of cell division will often be repaired, unless the
cell divides ﬁrst. Hence, even these mutational processes are proportional to the rate
of cell division.
We can now fully deﬁne our model in terms of chemical half-reactions in the Gille-
spie formalism:
 nd;np 
B nd;np 
               nd   ∆d;np   ∆p     nd   ∆d;np   ∆p 
 nd;np 
D N 
        ∅
Notice that population size can vary because of (i) accrued drivers, (ii) accrued pas-
sengers, and (iii) stochasticity in the birth & death rates. We can also deﬁne a ‘gener-
ation’ in terms of the mean division time:
1 generation  
 
 =N
∑N
i   B ndi;npi 
In general we use this measure of time for analysis, as it is a convention in population
12genetics.
Many of the above considerations and issues associated with formulating our model,
are germaine to all models of tumor progression, not simply the in silico models pre-
sented here. Consider that recent data on growth rates of human tumors diﬀers from
data obtain from mouse models: human tumors grow according to an exponential
curve13, while mouse tumors grow according to a Gompertz curve30. Careful mathe-
matical consideration of the diﬀerences between a model of progression where growth
is exponential, and one where growth is Gompertzian, should allow us to understand
when it is necessary to reﬁne the design of simulations and experiments, when these
minutia can be ignored, or, instead, when we should alter our conclusions.
2.2 Evolutionary parameters
The evolutionary system above is fully deﬁned by ﬁve parameters: sp, sd, d   Tp,
p   Td, and N . These parameters vary considerably between tumor types (and
the mutation rate even varies within tumor types72), so we explored a wide range
of values centered around literature best-estimates (table 2.1 on page 15). Though
driver and passenger alterations take many forms, we ﬁrst parameterized our model
using single-nucleotide substitution data, as these mutations have been more thor-
oughly quantiﬁed. In chapter 5 on page 68, we investigate both alterations and point-
mutations and estimate selection coeﬃcients from these data.
Because of extensive cancer heterogeneity and limited quantitative knowledge, we
varied all parameters by 2 to 3 orders of magnitude. The ranges we explored cen-
tered on values obtained from the literature (table 2.1 on page 15). The mutation
rate (                        ; range      –    ) approximates cells with a mu-
13tator phenotype75. Our initial equilibrium population size (N        cells; range
   –   ) was estimated from hyperplasias within a mouse colonic crypt observed 2
weeks after an initiating APC deletion24. The target size for drivers (Td       nt;
range 70 – 7,000) is approximately 10 potential hotspot mutations per gene (onco-
gene or tumor suppressor) times 70 driver genes111. This value was used in previous
simulations8 and is close to the 571 loci with recurrent mutations in colon cancer36.
The target size for functional (nonsynonymous) passengers (Tp           nt; range
       –       ) was estimated as     nonsynonymous loci per gene times 5,000 well-
expressed, non-cancer-related genes in cancer22. This value is comparable, but less
than, a previous estimate of 10 million deleterious loci in cancer7; does not attempt
to capture the    –    non-coding passenger mutations per cancer genome101,10; and
yet is thousands of times greater than Td. The chosen driver strength [sd    :  (i.e.,
10% growth increase per driver); range 0.01 – 1] was shown to be congruent with can-
cer onset8. Passenger deleteriousness (sp       ; range     –    ) was estimated
from to the eﬀects of near-neutral germ-line mutations in humans34 and randomly
introduced mutations in yeast41.
We consider death to be any process that prevents a cell from replicating indeﬁ-
nitely, i.e. necrosis, apoptosis, senescence, or diﬀerentiation. Thus, N represents only
cells capable of inﬁnite division and of carrying the (epi)genetic information in cancer.
For this reason, our model lacks asymmetric cell divisions, as this yields diﬀerenti-
ated cells. We ﬁrst explore the initial population size N  across two orders of magni-
tude. Hence, our model applies equally well to tumor subtypes dominated by only a
small cohort of cancer stem cells and subtypes where cancer may arise from progeni-
tor cells49. Later on, we will demonstrate that a population grown to a particular size
N is equivalent to a population initialized at N. This path-independence allowing us
14Table2.1: Evolutionaryparametersexploredinthisstudy. Weexploredourevolutionarymodelincorporating
driverandpassengermutationsacrossabroadrangeofparameters. Therangesweremotivatedbyliterature
estimatesdiscussedpreviously
83 andinsection2.2onpage13. Notethatinsimulationsd   Td andp  
Tp,hencetheentirephasespacecanbeexploredbyonlyalteringandTd=Tp,asalteringallthreeparameters
isredundant. Inchapter5onpage68wecompareourmodeltoepidemiologicalandgenomicdataandafﬁrm
thatthesepriorpublishedestimatesexplainthenewdatawell.
Parameter Symbol Estimate Range Citation
Mutation rate            -      75
Driver loci Td     70 - 7,000 39,111,8
Passenger loci Tp                -        7,14
Driver strength sd  :  0.001- 1 8,11
Passenger strength sp  :         -      41
Initial population size N      * 100 -10,000 24
*Estimated from labeled populations in mice colonic crypts 2 weeks
after an initiating APC deletion was induced.
to simplify dynamics and explain progression for any initial or intermediate popula-
tion size.
The most critical constraint of our model is that Td ≪ Tp. Without this property
a barrier to adaptation is not observed and inﬁnite mutation rates become optimal.
This constraint on target sizes for simulations is justiﬁed for a number of reasons. A
priori, it should be expected that deleterious mutations outnumber advantageous mu-
tations in natural populations simply because natural selection optimizes genomes to
their environment—implying that most changes will be neutral or damaging. Indeed,
most protein coding mutations and alterations were deleterious or neutral when in-
vestigated empirically in ﬂy51, yeast117, and bacterial genomes20. We consider only
moderately deleterious loci here  sp               —which nevertheless account
for most nonsynonymous mutations41,14. Deleterious mutations outside of this range
either do not ﬁxate or negligibly alter progression83.
There is also considerable evidence that Tp ≫ Td in cancer. As much as 10% of
15the human genome is well-conserved and likely deleterious when mutated61,68. Con-
versely, there are only approximately 100-200 potential driver genes21,39. If driver loci
include only a few speciﬁc sites per gene  10, then collectively drivers will constitute
less than one one-millionth of the genome. Also, accumulated passengers greatly out-
number accumulated drivers (table 1.1 on page 4). This implies that the target size of
passengers greatly outnumbers the target size of drivers, as selection can only increase
the frequency of advantageous mutations relative to deleterious mutations.
For most of our parameter range sd > sp, but we also explored exceptions to this
rule and captured their dynamics with our analytical model. The selection coeﬃcients
of drivers sd and passengers sp were estimated from genomics data in the main text
and found to be comfortably within the range we explored. Nevertheless, there was
good evidence for the range of ﬁtness beneﬁts for drivers before we began our study.
A previous study found that an sd of 0.1 is necessary to obtain waiting times to can-
cer consistent with age-incidence rates8. Later on, we discuss evidence from mice
models that support this approximate value of sd.
The mutation rate not only varies considerably between tumors72, but also varies
as a tumor evolves. We believe that genomic instability happens early during pro-
gression, as this has been shown experimentally some tumors109 and suggested to
be the ﬁrst event during progression by virtue of theoretical considerations96. How-
ever this presumably diﬀers from tumor to tumor. Thus, by developing a theoretical
understanding of the process, we hope to gain some intuitive understanding of how
variation in mutation rate over time might alter dynamics. For example, we show
later that for tumors far below the critical mutation rate  , variation in the mutation
rate increases or decreases the rate of accumulation of drivers and passengers equally.
However, near or above  , variation in the mutation rate has a profound impact on
16driver’s probability of ﬁxation and eﬀect size.
2.3 Previous evolutionary models of cancer progression
Two previous investigations of cancer progression have considered deleterious passen-
gers and found that they have a minimal impact on progression7,104. The ﬁrst paper
assumes that passengers are eﬀectively lethal to cancer cells (i.e. sp    ). They con-
clude that deleterious passengers are unimportant because they are quickly weeded
out of the population. This is consistent with our results (see chapter 3 on page 22,
or ﬁgure 4.1 on page 46), however we believe that our best-estimate of sp        is
more reasonable. Our justiﬁcation for this is discussed above, but also supported by
a lack of evidence for negative selection in cancer genomes (see ﬁgure 5.2 on page 75),
suggesting that deleterious passengers must be accumulating and cannot be lethal. In-
deed, we observe the accumulation of passenger mutations within housekeeping genes
and speciﬁcally at loci predicted to be deleterious by classiﬁcation algorithms (see ﬁg-
ure 5.1 on page 72). To us, this is clear evidence that sp cannot be large enough to
prevent the ﬁxation and accumulation of most deleterious passengers.
In the second study that models deleterious passengers as part of an inquiry on the
eﬀects of genomic instability104, the authors assume that there exist only  100 house-
keeping genes in cancer that are deleterious when mutated. Again, we observe similar
behavior in our simulations: when Tp   Td, passengers do not appreciably alter pro-
gression. However, our best-estimate of the number of relevant deleterious genes is
50  larger than their estimate (table 2.1 on page 15), while the paper discussed in the
preceding paragraph argues that Tp is even larger than our estimate (100  greater
than the estimate in this second paper7). There are two reasons for this discrepancy
17in parameter choice. First, the article considers only deleterious housekeeping genes,
while we believe many other genes and non-coding sequences (e.g. regulatory DNA
sequences or microRNAs) could potentially be deleterious to cancer cells104. Sec-
ondly, we ﬁnd that the number of reported housekeeping genes is much larger than
100 (3,804 genes are classiﬁed as ‘housekeeping’ in31, which also reviews other, sim-
ilar estimates). We believe most genes could be deleterious when mutated because
(i) it has been proposed that passengers might invoke an immune reaction to tumor
cells120, and (ii) because they may cause cytotoxicity via protein disbalance and ag-
gregation108. This later mode of damage should be applicable to nearly all expressed
genes within the tumor, which constitute more than half of the 26,588 identiﬁed genes
in the human genome31.
Lastly, the article104 remarks that passenger’s drag on population size weakens as
sp increases beyond 0.01. In our theoretical work below, we show that the optimum
sp for slowing progression s 
p is approximately proportional to the mutation rate of
passengers (s 
p   p). Hence, for the authors chosen target size of passengers, their
ﬁnding is correct; however, given our larger estimate of p (discussed above), increases
of sp beyond 0.01 continue to increase the drag of passengers on cancer progression.
Because the relevance of deleterious passengers depends upon evolutionary parame-
ters, their eﬀects may be neglected in certain circumstances. In ﬁgure 4.1 on page 46,
we identify the evolutionary regimes where passengers dominate, where they compete
with drivers, and where they can be probably be neglected. We believe and present
evidence that passengers are relevant for progression in most carcinomas, but we also
observe that lymphomas ﬁxate very few passengers (table 1.1 on page 4). All these
concerns underscore the importance of further investigating the evolutionary parame-
ters of cancer progression for various tumor types to ascertain passengers relevance to
18cancer progression.
2.4 Where to begin?
Before describing the entire dynamics of our model, it is useful to consider the dif-
ference between our simulations initiated at their stationary size (N  cells) and sim-
ulations initiated at 1 cell. In the absence of mutations, an initial population of one
cell will grow logistically until it reaches the stationary size. Hence, it takes approx-
imately Log  N     Log            generations for the initial cell to approach sta-
tionary size. This is far shorter than the average time required for cancer progres-
sion (    ;    generations) and the time required for a new driver to accumulate
(   = dN sd     ;    generations). Thus, our choice of initiating a tumor at one
cell versus N  does not signiﬁcantly alter the conclusions of our model.
This comparison of timescales also suggests that cancers are almost always near
their stationary size:
B nd;np    D N 
We test this conclusion in simulations and found that it is a excellent approximation
of tumor size (ﬁgure 3.9 on page 37). If we assume B nd;np    B nd;np , then a
relationship between the number of drivers and passengers in a tumor and its size is
19obtainable:
B nd;np    D N 
     sd nd
     sp np   Log    
N
 e     N  
ndLog     sd    npLog     sp    Log Log 
N
N   
ndsd   npsp   Log Log 
N
N      sd;sp ≪   (2.3)
This ﬁnal equation suggests that there exist a linear relationship between drivers and
passengers among tumors with similar sd and sp, which we assume is the case for
tumors of the same tissue of origin. The relationship should be relatively robust to
tumor size, but sensitive to the ﬁtness eﬀects of drivers and passengers. Moreover,
changes in the functional form of D N  will alter the y-intercept of this linear rela-
tionship, but not the slope of the relationship. Hence, we can draw conclusions about
the relative strength of drivers versus passengers (sd=sp) without knowing the exact
constraints on population size. We tested and veriﬁed this prediction of a linear rela-
tionship between drivers and passengers in chapter 5 on page 68.
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alter progression
3.1 Moderately Deleterious Passengers Fixate and Alter Cancer
Progression.
Figure 3.1 on the next page presents typical population trajectories of cancer begin-
ning at the ﬁrst driver mutation. All trajectories consist of intervals of rapid growth
and gradual decline. A new driver leads to a clonal expansion of the subpopulation
carrying this driver, causing short periods of rapid growth. Growth stops when the
eﬀect of this driver is balanced by the death rate, which increases with population
size. While the population waits for the next driver to arise, passengers steadily accu-
mulate, causing a gradual decline of population size. Together, these processes cause
trajectories to grow in a sawtooth pattern. Simulated tumors exhibit either uncon-
strained growth or regression, often after a period of dormancy (ﬁgure 3.1 on the fol-
lowing page).
The phenomena of dormancy and spontaneous regression, observed both in our
model and clinically2, do not occur in models lacking deleterious passengers.
Importantly, simulations show that hyperplasias that progress to clinical size (i.e.,
    cells) accumulate many deleterious passengers. This evasion of purifying selection
and ﬁxation of deleterious passengers is an unexpected result not programmed into
22Figure3.1: Precancerouslesionscanremaindormant,rapidlygrowtocancer,orregress. Despiteidentical
parameters,simulatedcancerprogressiontrajectoriesexhibitmarkedlydifferentbehavior. Somepopulations
regresstoextinctionorexhibitlongperiodsofdormancy. Theaccumulationofstronglybeneﬁcialdriversalong-
sidemoderatelydeleteriouspassengersresultsinareversed-sawtoothedpatternofgrowth.
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Figure3.2: Passengersaccumulateacrossabroadrangeofmutationratesandpassengerdeleteriousness.
(Left)Thenumberofaccumulatedpassengersincreaseswithmutationrateanddepends,non-monotonically,
onpassengerstrength. Passengersaccumulateexceedinglyslowlyoncethepopulationsizeoftheﬁttestclass
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41.
the model. Although the exact number of accumulated passengers depends on  and
sp (ﬁgure 3.2),           deleterious passengers are obtained for a broad range of pa-
rameters, consistent with the numbers of nonsynonymous substitutions observed in
cancer genomics studies (table 1.1 on page 4), suggesting that observed passengers in
sequencing data can be moderately deleterious.
Figure 3.2 shows that moderately deleterious, rather than highly deleterious or neu-
tral, passengers have a major eﬀect on cancer progression. Indeed, almost-neutral pas-
sengers have very little eﬀect on cancer cells, and passengers of large eﬀect do not
accumulate7. By slowing progression to cancer, moderately deleterious passengers
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25accumulate in even greater numbers than neutral mutations despite their slower ac-
cumulation rate (ﬁgure 3.2 on page 24). Importantly, we ﬁnd that moderately delete-
rious passengers aﬀect progression for sp from      to         , which subsumes the
best literature estimates of the strength of deleterious mutations41,34. Such small se-
lection coeﬃcients for individual passengers are typically undetectable in cell cultures,
yet critical for long-term cancer dynamics.
3.1.1 Passengers accumulate via genetic draft and Muller’s Ratchet
We then studied how deleterious mutations can accumulate despite negative selection.
Previous studies have calculated the rate of accumulation of deleterious mutations in
the absence of clonal expansions16,47,92. In ﬁgure 3.4 on page 28, we identify two pre-
viously known processes that allow passengers to evade negative selection in cancer:
hitchhiking alongside a driver and Muller’s ratchet33. Deleterious passengers hitchhike
when the cell they reside in acquires a new driver, which then leads to a clonal expan-
sion and ﬁxation of all the mutations in that cell. Muller’s ratchet, in turn, is a pro-
cess of gradual accumulation of deleterious mutations and population decline in the
absence of drivers. In Muller’s ratchet, a mutation-selection balance arises after driver
sweeps, which creates a steady-state Poisson distribution of the number of passengers
per cell with mean and variance p=sp (ﬁrst described in ref.53 and discussed further
in chapter 4 on page 41). The ﬁttest subpopulation—cells with the fewest passengers:
Np     Ne p=sp cells—is much smaller than the whole population, so it can spon-
taneously shrink to extinction (ﬁgure 3.4 on page 28). When back mutations are rare,
such an extinction leads to the irreversible loss of this least-mutated fraction of cell
and corresponds to a ‘click’ of Muller’s ratchet33. This process is especially rapid dur-
ing clonal expansions when the size of the expanding clone is small. Both of the above
26processes, well known in population genetics, are augmented in cancer because of the
presence of strong drivers.
3.1.2 Various distributions of passenger strengths exhibit similar be-
havior to fixed-effect model
We then relaxed our assumption that sd and sp are constant for all passengers, by
simulating cancer progression with drivers/passengers drawn from distributions of
eﬀect sizes (ﬁgure 3.5 on page 30). There does appear to be some greater variation in
the waiting time to cancer when drivers drawn from a distribution of eﬀect sizes are
used. However, the overall dynamics appear qualitatively similar, and suggest that
our model is a good approximation of more sophisticated models.
Like drivers, we simulated trajectories with passenger mutations drawn from several
potential ﬁtness distributions94. The eﬀect of each passenger x, was drawn from ei-
ther an exponential distribution, a Log-Normal distribution, or a Gamma distribution
with the following density functions.
                          =      
 
LN  x sp   
 
x
 
 
     
      =       
   
 
 
  x k    ;sp    s  
p x       =   
All distributions have a mean value of sp of 0.001.
The strength of passenger mutations aﬀects their ﬁxation probability. For passen-
gers, the variation in ﬁtness within a population is mostly invariant to the type of dis-
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28tribution of passenger eﬀects (ﬁgure 3.6 on page 31). Negative selection against pas-
senger ﬁxation appears to be largely ineﬃcient, except for highly deleterious passen-
gers (ﬁgure 3.5 on the following page). The signiﬁcant variance in cell ﬁtness within
the population, caused by deleterious passengers (ﬁgure 3.6 on page 31), also aﬀects
the probability of driver ﬁxation. Because a driver will generally occur in a cell of av-
erage ﬁtness, it is unlikely to ﬁxate unless its new ﬁtness is greater than the ﬁttest
cells. The diﬀerence between the ﬁttest cells and average cells in the population is
approximately p and independent of sp (ﬁgure 3.6 on page 31)44; therefore, a driver
must confer a beneﬁt greater than p to ﬁxate (discussed in detail in section 4.2 on
page 63). This argues that weak drivers are unlikely to ﬁxate in cancer or be observed
in genomic sequencing.
The interplay between the deleterious mutation rate and variance in population
ﬁtness suggests that precancerous populations with larger mutation rates will ex-
hibit suppressed levels of negative selection. Indeed, this appears to be the case for
exponentially-distributed passenger eﬀect sizes (ﬁgure 3.6 on page 31). This ﬁnding
may be testable in future genomic studies by investigating the degree of purifying se-
lection in sequenced cancer genomes and comparing this value to the cancer’s overall
mutation rate and each mutation’s expected deleteriousness.
In section 4.3 on page 65, we discuss an analytical model of passengers with varying
eﬀect size that is inspired by the results in this section.
In summary, our simulations demonstrate that despite the moderately deleterious
eﬀect of individual passengers, they accumulate in large numbers during neoplastic
progression, reducing the ﬁtness of cancer cells and altering the course of neoplas-
tic progression. We ﬁnd several reasons why deleterious passengers accumulate more
than might be expected a priori: (i) mutator phenotypes [a hallmark of cancer75] ac-
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divisionwithratep. Passengerswithveryweakdeleteriousnessarebothmorefrequentinthedistributionand
ﬁxatemoreoften. (B)Weakpassengersﬁxateatanearlyneutralrate,whilestrongpassengerscanbeweeded-
outbynaturalselection,howeverthisbecomeslesslikelyasthemutationrateincreases. (C)Populationdynam-
icsdonotchangenoticeablywhenpassengersweredrawnfromvariousdistributionsofﬁtnessdistributions
(describedabove). Thevarianceinﬁtnessisproportionaltothemutationrateandmuchlargerthanthemeanef-
fectsizeofpassengers(i.e. p >   sp). Thus,mostpassengerssegregateinthepopulationforanextendedperiod
oftime,affectdynamics,andcanﬁxateviageneticdraftinadditiontoMuller’sRatchet.
celerate accumulation rates; (ii) small population sizes in the early stages of cancer
progression enhance accumulation rates; (iii) driver-induced bottlenecks and hitch-
hiking contribute additional passengers; (iv) passengers prolong progression—oﬀering
more time for accumulation; and (v) passengers arising as part of a distribution of
deleteriousness ﬁxate more often than equivalent passengers considered in isolation.
These ﬁrst three phenomenon, though undocumented in cancer theory, have been pre-
viously observed in population genetics78.
313.2 Passengers can prevent cancer progression when tumors are be-
low a critical population size
3.2.1 A critical population size
Figure 3.8 on page 35 shows the dynamics N t  of individual populations starting
at diﬀerent initial sizes N , which correspond to diﬀerent potential hyperplasia sizes
(trajectories begin immediately after a stem cell acquires its ﬁrst driver, see section 2.4
on page 19 for a discussion of dynamics before this point). Populations exhibit two ul-
timate outcomes: growth to a macroscopic size (i.e. cancer progression), or extinction,
which depend on a critical population size N . Larger populations  N > N   gener-
ally commit to rapid growth, while smaller populations  N < N   generally commit to
extinction.
To understand the origin of this critical population size N , we examined the short-
term dynamics of populations. All trajectories follow a reversed saw-toothed pattern
(ﬁgure 3.8 on page 35), resulting from a tug-of-war between drivers and passengers.
When a new driver arises and ﬁxates in the population, the population size increases
to a new stationary value. In between these rare driver events, the population size
gradually declines due to passenger accumulation. The relative rates of these compet-
ing processes determine whether a population grows rapidly or goes extinct.
The value of N  can be identiﬁed by considering the average change in population
size over time (⟨dN=dt⟩), which is the average population growth due to accumulating
drivers (vd) minus the population decline due to accumulating passengers  vp . When
a new driver ﬁxates, the population size immediately increases by ∆N   Nsd. These
jumps occur randomly at a nearly constant rate f   dNsd (a product of the driver
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Figure3.7: Tug-of-warbetweendriversandpassengersleadstoacriticalpopulationsize. Populationsize
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torapidgrowth,whilesmallerpopulationscommittoextinction,andintermediatepopulationsbifurcate. Acriti-
calpopulationsizeN  appearstoseparatethetworegimes.
33occurrence rate dN, and its probability of ﬁxation sd=     sd    sd). Thus, the
velocity due to drivers is vd   f∆N   dN s 
d. Similarly, passengers’ velocity vp  
pNsp is a product of their rate of occurrence pN; eﬀect on population size Nsp;
and ﬁxation probability (   =N when passengers are near-neutral, see chapter 4 on
page 41 for more precise estimates). Thus, we obtain:
⟨
dN
dt
⟩
  pspN
(
N
N     
)
(3.1)
N   
Tpsp
Tds 
d
(3.2)
Here, N  is the critical population size. In this equation, a population’s mean velocity
is negative below N  and positive above N , explaining why populations above N 
grow rapidly and populations below N  continually decline.
These dynamics suggests that N  constitutes an eﬀective barrier to cancer, which
can prevent most cancers from progressing (ﬁgure 3.8 on the following page) . Simu-
lations support this conclusion, as they exhibit a sharp transition in the probability of
progression at N  (ﬁgure 3.8 on the next page). Indeed, drastically diﬀerent probabil-
ity curves collapse onto a single curve when N  is rescaled by N .
By considering only the average dynamics, we miss the variability of outcomes in
adapting populations. In the next chapter, we formulate and solve a stochastic gener-
alization of equation (3.1) that explains the variability of outcomes well. Outcome
variability depends only upon N  and the strength of drivers sd. Higher values of
sd lead to larger stochastic jumps ∆N, which increases variability and leads to more
gradual changes in the probability of cancer across N .
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353.3 Effects of various models of epistasis
Here, we consider two alternative models of epistasis between mutations: a model
where mutations interactive additively (rather than multiplicatively), and a ‘two-hit’
model where the ﬁrst driver mutation confers no ﬁtness beneﬁt. This later model
is meant to approximate certain tumors, particularly blood cancers, where initial
proliferation-rate-increasing mutations are only beneﬁcial once apoptotic barriers are
eliminated via further driver mutations.
In our additive model, we assume that the ﬁtness beneﬁt and costs of drivers and
passengers is sdnd   spnp. This model lacks the symmetric properties of mutations in
our multiplicative model and deﬁes the commonly-used deﬁnition of absolute ﬁtness
for a mutation: s           Nafter
Nbefore. However, ﬁgure 3.9 on the next page demonstrates
that it behaves qualitatively similar to our original model.
3.3.1 A two-hit model of cancer progression
It has been proposed that driver mutations may only be beneﬁcial in a certain genetic
context6. Oncogenes like c-Myc and k-Ras have been shown to induce senescence in
some cancer cell lines unless they are accompanied by mutations in p53 or other as-
sociated proteins32. Likewise, many tumor suppressors mutations are recessive and
require a second ‘Loss of Heterozygosity’ (LOH) event to impart their phenotypic ef-
fects (although many tumor suppressors are at least partially haploinsuﬃcient). These
types of mutations can be thought of as operating via a two-hit processes: the ﬁrst
driver event confers no change to cell ﬁtness, while the second genetic event confers
the beneﬁt of both mutations.
Two-hit models have been studied previously in cancer evolution (Refs.58,88,96 to
36Figure3.9: Additiveandmultiplicativeepistasisbehavesimilarly. (A)Sixtrajectories(blueshades)with
ratesB nd;np   
(1+sd)
nd
(1+sp)np andD N    N
N0 appearqualitativelysimilarto(B)simulationswithrate
B nd;np        sdnd   spnp andanidenticaldeathrate. Theyarealsomathematicallyequivalenttoﬁrst
orderexpansionof nd;np . BlacklinesrepresentN whichsatisﬁesD N    B nd;np . Thestrongoverlap
ofthisblacklinewiththeobservedpopulationsizeindicatesthatbirthanddeatharebalancedthroughoutpro-
gression. Forthisreason,amodelwheremutationsalterdeathrates,ratherthanbirthrates,wouldbeequivalent
toourmodelprovidedthattimeismeasuredinunitsofgenerations.
37name a few), but never in the presence of frequent moderately-deleterious passenger
mutations. For this reason, we considered our originally deﬁned model above, modi-
ﬁed such that the ﬁrst driver mutation confers no beneﬁt to the cell, while the second
driver mutation confers the beneﬁt of both mutations, and all remaining mutations
confer a beneﬁt of sd. Hence,
w nd;np   
 
     
     
     sp np; if nd <  
     sd nd     sp np; otherwise
We kept all other properties of the model the same and investigated the result of
this permutation in ﬁgure 3.10 on page 40. We observe three changes: (1) while the
critical barrier to progression remains, its location N  increases; (2) trajectories slowly
decay in a long period of stasis that allows additional passengers to accrue and delays
progression; (3) the transition from the non-adaptive to adaptive regime is slower, as
the period of stasis is highly variable. We can understand these observations by ﬁrst
considering the mean time of stasis (time until the second driver mutation ﬁxates) for
the population. The probability that a second driver ﬁxates in the population at time
t is simply the probability that a cell already harbors the ﬁrst driver mutation (dt),
times the total number of cells in the population (N e vpt), times the probability that
the second driver arises and sweeps through the population (d
 sd
   sd). Hence, the
probability that stasis will end at generation t is P     t    N  
d
 sd
   sdte vpt. Thus,
the probability that stasis last a certain number of generations P       t  is the proba-
38bility of not exiting in the prior generations and also exiting at generation t:
dP       t     P     t dtP       t 
P       t    e 
∫ t
0 Pexit t′ dt′ (3.3)
From simulations (ﬁgure 3.10 on the next page), it is clear that most simulations
that exit this early stasis period go onto progress to cancer. Hence to a ﬁrst approxi-
mation, the new N ;        is the value of N , where P            , thus:
        
∫  
    ;        
 
  d
    d    p   
N ;         
          d  2
p
 2
dsd
This predicts N ;        to be 883 for the trajectories plotted, which is within a factor
of two from the 50% success point. It is somewhat below the observed tradition point
presumably because (i) trajectories that exit this stasis period far below N  never
progress, and (ii) segregating passengers may interfere with the ﬁrst beneﬁcial driver.
Collectively, these results suggest that our mathematical framework of our model is
generally applicable to cancers where the ﬁrst driver isn’t beneﬁcial, but that there
are also some dramatic diﬀerences that warrant further investigation.
While two-hit models of progression are most likely applicable in many tumors, we
do not believe that these models are more universal than our original formulation.
Consider that in experiments directly measuring the change in cell ﬁtness upon ac-
tivating mutations in k-Ras, an immediate increase in proliferation was observed119.
Also, many tumor suppressors are haploinsuﬃcient (e.g. Dicer69, p27100, CDC480,
p1899). These results suggest that driver mutations are often advantageous, after only
one mutation.
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An analytical deconstruction of drivers
and passengers
4.1 An analytical model of dynamics
In chapter 3 on page 22, we demonstrate that dynamics are described by two coun-
teracting forces: an upward velocity vd resulting from accumulating beneﬁcial drivers,
41and a downward velocity vp resulting from accumulating deleterious passengers. The
upward velocity vd was further subdivided into a product of the rate at which new
drivers ﬁxate in the population f times their eﬀect on population size once ﬁxated
∆N (ﬁgure 3.8 on page 35) *. The velocities vd and vp are balanced at a critical pop-
ulation size N , at which the population is approximately equally likely to go extinct
or progress to cancer.
While we were able to describe the average behavior of our population (chapter 3
on page 22), our system, like cancer, is inherently stochastic. Its complete dynamics is
best described by a diﬀerential equation with stochastic jumps:
dN   vpdt   ∆Ndnd
nd  
f
    nd    
(4.1)
In this equation, the change in population size dN is the product of a deterministic
component  vp, along with a stochastic component describing the random arrival of
new drivers  ∆Ndnd . Below, we use this equation to estimate the probability of can-
cer for any population size P       x  and the mean waiting time to cancer t       x ,
where x   N=N  is a dimensionless population size brieﬂy discussed in the previous
chapter and more thoroughly discussed below. Lastly, we noticed that simulations dif-
fered from the formalism we presented in the previous chapter, if the mutation rate
 increases beyond     , or if we explore a broader range of passenger deleterious-
ness sp (ﬁgure 4.1 on page 46). These discrepancies are resolvable by considering two
phenomena neglected in our ﬁrst derivation: selection against passengers, and passen-
*While we assume that drivers arise at random time intervals, this assumption is not al-
ways true. Because unﬁxed passengers can interfere with the ﬁxation of drivers, a driver is
more likely to ﬁxate immediately following a previous driver ﬁxation event57. Ignoring this
caveat does not signiﬁcantly alter dynamics in the parameter space explored here.
42ger’s eﬀect on both the ﬁxation probability and clone ﬁtness of drivers. Fortuitously,
accounting for these phenomena does not alter equation (4.1) on the preceding page,
nor the overall framework of our analytical model. Instead, they only aﬀect the rates
vp, f, and jump size ∆N in our model. Thus, with the reﬁned formalism, we can
describe dynamics across a very broad range of parameters (ﬁgure 4.1 on page 46).
More importantly, we observe drastic reductions in the probability of adaptation at
high mutation rates and encompassing moderately deleterious passengers. These ﬁnd-
ings suggest novel strategies to cancer therapy discussed in chapter 6 on page 88.
From equation (4.1) on the previous page and ﬁgure 4.2 on page 47, it is evident
that population size is the state variable of our system and, as such, is all that is
needed to describe future dynamics. By converting population size into a dimension-
less parameter x   N=N  (and x    N =N ), the probability of cancer collapse onto
a simple curve P       x  (ﬁgure 3.8 on page 35)—further underscoring the importance
of the critical population size. Hence, we will use this dimensionless quantity x heav-
ily throughout the remainder of our analysis.
434.1.1 Estimating the probability of cancer
Using equation (4.1) on page 42 we can describe how the probability of extinction
changes in an inﬁnitesimal time due to either passenger accumulation or a rare driver
jump:
P       x    f x dtP       x   ∆N x          f x dt P       x   vp x dt 
In this equation, we see that is the probability of cancer at x is the probability of
a jump times the probability of cancer after the jump (f x dtP       x   ∆N x  )
plus the probability of decline times the probability of cancer after the decline (    
f x dt P       x   vp x dt ). Note that f, ∆N, and vp are all functions of x in the
equation above. Deﬁning these functions in such a general form makes solving the
stochastic diﬀerential equation impossible. So we note that each function is approxi-
mately linear in x. Thus, we can replace each function with a constant times x: f x   
fx, ∆N x    ∆Nx, and vp x    vpx.
The probability of cancer after a decline can be expanded via a Taylor series: P       x 
vpxdt    P       x    vpxdtP′
       x . Along with the linear approximations we made
for f and , this reduces the above equation to:
vp
f
P′
       x    P       x    P       x  (4.2)
Here,        ∆N       sd denotes the logarithmic change in population size
after a driver jump. Next we notice from simulations that P       x  changers most
signiﬁcantly when x is near 1. Hence, we can logarithmically-transform x and solve
44Figure4.1: Analyticalframeworkpredictsprobabilityofcanceracrossparameterspace. Theprobabilityofpro-
gression,determinedfromtheoutcomeof3,000simulations(foreachdata-square)propagateduntilextinction
orrapidgrowth,acrosstheparameterrangeofourmodel. Insimulations,weobserveparameterswhereprogres-
sionoccurs,fails,andisrare. Asophisticatedanalyticalframeworkincorporatingselectionagainstpassengers,
hitchhikingofpassengersontodrivermutations,andstochasticityinpopulationsizepredictsobservationswell
(blacklines). ThissophisticatedanalyticalmodelusestwosolutionsforMuller’sRatchetinvariousparameter
regimes(seesection4.1.3onpage53),anestimateofthequantityofhitchhikingpassengers(seesection4.1.4
onpage57),andastochasticdifferentialequationofthepopulationsizetoestimateprobabilitiesofprogres-
sion(seesection4.1.1onpage44). Asimpliﬁedframework,whichoffersaclosed-formsolution,ispossibleand
worksreasonablywell(magenta). Thissolutiondiffersfromthemoreprecisesolutionintwoways: (1)anovel,
simpliﬁedestimateofMuller’sratchetisused(Eq. 4.8),and(2)weneglecthitchhikersthataccumulateaftera
newdriverclonearises(i.e. pS    ). (A-A′′′)Pcancer increasesforallparameters,astherelativetargetsizeof
driversTd versespassengersTp increases. (B-B′′′)and(A′′′)Pcancer exhibitsalocalminimumversestheselec-
tionagainstpassengerssp. Whenselectionagainstpassengersisveryweak,passengersareeffectivelyneutral.
Whenselectionagainstpassengersistoostrong,naturalselectionpreventspassengersfromaccumulating. Dele-
teriouspassengersaremosteffectiveatpreventingcancerwhenmoderateineffectsize. Thelocalminimum
suggeststhattheremaybetwotypesofcancers: thoseexistinginanenvironmentorgeneticcontextwherepas-
sengersareweak,perhapsbufferedbyanactivatedUPR;andthosethatsucceedbyexacerbatingpassengers’
deleteriouseffects,perhapsbydecreasingtheirmutationrate(seeB’).(C,C′,A′′,B′′)Theprobabilityofcancer
alwaysincreaseswithsd. Thisparameterhasaprofoundaffectoncancerprogressionasitincreasestheben-
eﬁtofdriversandtheirprobabilityofﬁxation. Hence,theboundarybetweensuccessandfailureappearstobe
almostindependentoftheotherparameters. (D)and(A′)Anincreasingmutationrateaffectstheprobabilityof
cancerverylittleatﬁrst;however,onceitexceedsacriticalvalue(    sd=Tp,section4.2onpage63),the
probabilityofcancerdropsprecipitously.
45Figure4.1: (continued)
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Figure4.2: Simulationsexhibitpathindependence. (A)The12trajectoriesfromFigure1A,initiatedatN0  
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demonstratingthatpopulationsbeginningatdifferentinitialsizesN0 willbehavesimilarly,iftheyhavethe
samecurrentsize. Thus,populationsexhibitpathindependenceandcanbefullydescribedbyonestatevariable:
x   N=N0.
this new variable y   log x  via a Maclaurin Series:
vp
f
dP       y 
dy
  ey P y   Log      P y  
  ey Log  
dP       y 
dy
 
 
 
Log   
d P       y 
dy    ::: 
Now, by reverting from y back to x, we obtain:
vp
f
P′
       x    Log  xP′
       x   
 
 
Log   x P′′
       x   
 
 
Log   xP′
       x  (4.3)
By eliminating the last term in this solution, a reasonable approximation because
Log    ≪  , the diﬀerential equation is now solvable. Its boundary conditions (es-
47sentially the deﬁnitions of cancer and extinction) are:
P       x         
P       x         
The probability of cancer after inﬁnite time is (demonstrable by substitution in equa-
tion (4.3) on the previous page):
P                
Log  ;  
Log  x  (4.4)
Here,  s;x     =  s 
∫ x
  e tts  dt     s   
∫  
  xs  e x  x is the normalized incom-
plete gamma function. This solution is parameterized by two dimensionless quantities:
 and x, which represent the jump size in population of driver sweeps and our eﬀec-
tive population size respectively.
4.1.2 Estimating the mean time to progression
We can also use equation (4.1) on page 42 to solve for the waiting time to cancer.
This can be accomplished in two ways: (1) we can simulate random driver jumps and
deterministic passenger decline directly, and (2) we can approximate the mean wait-
ing time to cancer using a Taylor expansion similar to the strategy we employed to
solve for the probability of cancer. These two approaches agree with each other (thus,
illustrating their accuracy), and oﬀer key insights into the evolutionary parameters
that aﬀect age-incidence curves (ﬁgure 4.3 on the next page).
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demonstratethattheshapeofourpredictedage-incidencecures(below)shoulddependalmostentirelyonsd
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49equation (4.1) on page 42 can be simulated using a “hybrid” Gillespie algorithm: a
meta-simulation of driver- and passenger-accumulation events that we, originally, ob-
served arising from our atomistic simulations of birth, death, and mutational events.
The advantage of this technique is that it allows us to quickly simulate billions of tu-
mors, which would be computationally impossible via full-detail simulations. Because
we are conﬁdent that we are accurately estimating the rate of driver and passenger
accumulation events (ﬁgure 4.1 on page 46), this simpliﬁcation should retain accuracy.
To simulate equation (4.1) on page 42 directly, we must consider that the instanta-
neous probability of a driver jump f x t   is a function of a constantly declining popu-
lation size due to passenger accumulation: x t    xnd     sp vp=spt   xnde vpt. Here,
xnd is the population size after the last driver jump. Thus, the waiting time between
drivers ∆t   tnd     tnd is:
∫ ∆t
  fN t′ dt′   
f
∫ ∆t
  Nnde vpt′
dt′   
∆t      
vpLog    
vp
fNnd
 
(4.5)
 is an exponentially-distributed random number with mean 1. Using our precise
calculations of f, vp and ∆N below, we can now simulate equation (4.1) on page 42
directly.
We can also solve equation (4.1) on page 42 for t      , using the exact same ap-
proximations as we did to estimate P       x . To do this, we begin with a Master
Equation for the probability of acquiring a cancer after waiting time t when currently
at size x:
50P       x;t    f x t P       x;t   t         f x t P       x   vp x t;t   t 
The mean waiting time to cancer is then:
t       x   
∫  
 
tP       x;t dt
Before substituting the Master Equation into this deﬁnition, we must ﬁrst utilize a
ﬁrst-order Taylor series expansion about  and t:
P       x;t   t    P       x;t   
@P       x;t 
@x
        
@P       x;t 
@t
t
This leads to the solution:
t       x   
∫  
 
P       x;t tdt   t
∫  
 
@P       x;t 
@t
tdt
   ft        
(
    f
)(
vpt
)
 
∫  
 
@P       x;t 
@x
tdt
The ﬁrst integral in this solution is simply the deﬁnition of our mean waiting time
(t       x ). The second integral can be integrated by parts by noting that    t   tP       x;t   
  (otherwise, t       x  would be undeﬁned). Lastly, the third integral reduces to
t′
       x . Thus, we eventually ﬁnd:
f x  c x    c x     vp x ′
c x    P       x     
51Here, c x    P       x t       x . This equation has a nearly identical form to
equation (4.2) on page 44. So we used a similar Second-Order Maclaurin series expan-
sion of Log x  to approximate its solution:
t       x   
 
fLog   
[∫  
x
dy
y 
P       y      P       y  
P′
       y 
 
    P       x 
P       x 
∫ x
 
dy
y 
P 
       y 
P′
       y 
]
(4.6)
These integrals can be numerically computed using Simpson’s Method and yield a
solution that is in good agreement with the hybrid simulations described above (ﬁg-
ure 4.3 on page 49).
Our solution for the waiting time to cancer is most illustrative when x ≪  —the
regime that we expect to contain most tumors. In this regime, the mean time of can-
cer progression increases as  Log x =vp, which implies two interesting properties of
t      . First, x has a very weak, sub-linear, eﬀect on the waiting time and does not
signiﬁcantly alter the shape of incidence curves (discussed in chapter 5 on page 68).
Second, the waiting time to cancer is dictated by vp (the accumulation rate of passen-
gers), thus oﬀering yet another reason to continue investigating the rate of deleterious
passenger accumulation.
The mean time to cancer t       x  is a quantity that is conditioned on a popula-
tion actually progressing to cancer. Hence, it depends heavily on the probability of
adaptation P       x . Because P       x  has an inﬂection point at x    , the mean
waiting time to cancer t       x  behaves very diﬀerently when x >  , than when
x <  . When x >  , the mean waiting time is approximately t        
∫  
<dN=dt>dN,
i.e. the solution behaves as we would expect from our mean solution—as nearly all
52cancers succeed. However, when x <  , the mean waiting time to cancer deﬁes mean
behavior, as the mean cancer goes extinct. Only the rare, exceptional populations
that progress to cancer are weighted in the mean of t       x ; these exceptional popu-
lations grow much faster than the average population. Hence, the increase in waiting
time to cancer is sub-linear with respect to x when x <  .
4.1.3 Accumulation of deleterious passengers
Passenger mutations accumulate and drag populations down with a rate vp. This
quantity is a product of passenger’s arrival rate pN, their ﬁxation probability p,
and their eﬀect on population size once ﬁxated Nsp (i.e. vp   pspN, when p    
N).
In the previous chapter, we assume that the ﬁxation probability is approximately
neutral (p    =N); however, when selection is stronger that genetic drift, the ﬁxa-
tion probability becomes less than the neutral rate. A number of studies have focused
on the ﬁxation probability of deleterious mutations in a population, termed Muller’s
Ratchet92,48,16,47. In general, estimates of Muller’s Ratchet (and consequentially p)
begin by considering the distribution of deleterious alleles in a population of inﬁnite
size in mutation-selection balance—where allele frequencies are not changing. At equi-
librium, such a population exhibits a Poisson distribution in the number of segregat-
ing passengers p within a cell Np, deﬁned by a characteristic parameter p   p=sp
(ﬁgure 4.4 on the following page):
Np   N
e p
p
p
p 
(4.7)
If we then consider a population of ﬁnite size, we ﬁnd that the allele frequencies
ﬂuctuate due to genetic drift. If ﬂuctuations in the ﬁttest class (Np     Ne p)
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54are large enough to cause this ﬁttest class to go extinct, then it is irrevocably lost
from the population. This irrevocable loss is considered a ‘click’ of Muller’s Ratchet.
The new ﬁttest class—individuals harboring one segregating passenger prior to the
‘click’—then relaxes to a new equilibrium that ﬂuctuates, and the process repeats.
Estimating the time required for a new ﬁttest class to relax to equilibrium size im-
mediately following a ‘click’ is non-trivial and dependent upon the parameters of the
system: N, sp, and p, which can vary by orders of magnitude depending upon the
evolutionary system in question; hence there are many estimates of the exact rate of
Muller’s Ratchet.
We present and utilize 3 estimates of the rate of Muller’s Ratchet: (1) a solution
that works well for most values of sp, p, and N considered here (ﬁgure 4.1 on page 46)
and simply ignores the time to equilibration after ‘clicks’; (2) a traveling-wave so-
lution accurate for large values of p
16 that allows the distribution of segregating
passengers to be far from equilibrium, but presumes that that the size of neighbor-
ing mutational classes are uncorrelated; and (3) a solution accurate for small values
of p
47 that considers correlations between neighboring ﬁtness classes, but requires
that the population be in quasi-equilibrium (i.e. near mutation-selection balance).
Estimates (2) and (3) accurately describe Muller’s Ratchet across complimentary re-
gions of our phase space. By combining these later two estimates with estimates of
the number of hitchhiking passengers and their eﬀects on the probability of driver ﬁx-
ation events, we developed a precise description of our model’s dynamics (ﬁgure 4.1
on page 46 black lines).
If we simply ignore the equilibration time of a population into mutation-selection
balance, then we can estimate the rate of Muller’s Ratchet with a closed form solution
that is applicable to all values of sp, p, N investigated here. We assume that the
55probability of a ‘click’ is approximately the probability of a new passenger ﬁxating
within the ﬁttest class: Np     Ne p. In other words, to a ﬁrst-approximation,
deleterious passengers simply reduce the eﬀective population size of our system, such
that Ne   Ne p. The probability of a lone deleterious allele ﬁxating within this
ﬁttest class is describe by a Moran Process95. Hence,
   
p  
sp
     sp Ne    
(4.8)
This reﬁned ﬁxation probability 
   
p is then used to correct the downward velocity
due to passengers, using the same formula for vp derived in the main text:
v i 
p   pspN i 
p (4.9)
This equation links vp to the passenger ﬁxation probabilities calculated above, and
the other two ﬁxation probabilities calculated below.
The solution for Muller’s Ratchet as a traveling wave, which we apply when p <  ,
was obtained from16:
Log 
Nsp  
p
 
p
     

   
p
 
 Log  
e

   
p
      
 
 
p
Log 
 
   
p   = 
√
    pi
   
p
Log  e
p 
    
   
p Log  e
p     
 p
  (4.10)
Because this equation is transcendental, we solved for 
   
p using Brent’s Method.
When p    , a quasi-stationary analysis of the mutation classes becomes appropri-
56ate. This analysis was ﬁrst done in ref.47, resulting in a solution of the form:
Tclick  
e    
sp
e
spNp=0
2(e 1) (4.11)
The ﬁxation probability is then simply the inverse of the ‘click’ time: 
   
p    =Tclick.
Lastly, there is a discontinuity between the above two solutions at their intersec-
tion: p    . We resolved this by interpolating between the two solutions, as follows:
          
p   p   
p        p    
In essence, we have utilized three diﬀerent solutions for the accumulation of dele-
terious passengers, applicable in various parameter regimes: a neutral approximation
utilized in chapter 3 on page 22, a traveling-wave solution, and an estimate based on
ﬂuctuations in Muller’s Ratchet. Figure 4.5 on the following page illustrates the ac-
curacy of these three solutions and their applicability by highlighting their domain of
intended use and comparing them to simulations without advantageous drivers.
4.1.4 Effects of deleterious passengers on fixation probability and
clone fitness of drivers
The occurrence and ﬁxation of driver mutations are rare events, separated by nearly
random time intervals, with a frequency of occurrence f   dNd. Here, d is the
ﬁxation probability of a new mutant driver once it arises in the population. In the
mean velocity model presented in the previous chapter, we estimate that d   sd=    
sd    sd. However, this result assumes that there are no other non-neutral alleles in
the population. In reality, there are many segregating passengers in the population,
and potentially other segregating drivers.
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58The presence of other drivers in the population, which interfere with the ﬁxation of
our clone of interest, is a phenomena commonly described as Clonal Interference46.
Clonal Interference becomes signiﬁcant in the population once the time required for a
driver to ﬁxate [  Log N =sd generations] approaches the ﬁxation rate (f   dNsd).
Nascent precancerous population are in a space of evolutionary parameters where
Clonal Interference is particularly negligible: population size is small (N      ), and
drivers are rare (d       ), but strong (sd       ). Thus, we do not consider its
eﬀects here. However, for a larger tumor population, clonal interference may become
very signiﬁcant. This is especially true in a poorly-mixed population, where beneﬁcial
alleles take longer to sweep through the population66.
Segregating passenger mutations can also interfere with a driver sweep by ‘hitchhik-
ing’ on the expanding clone57,5. Hitchhiking passengers are critical for understanding
population dynamics at high mutation rates, so we will now consider their eﬀects in
detail. Most of the analysis we present has already been performed in two previous
works57,5, however it is integral to our derivation of the critical mutation rate and
must be extend to very high mutation rates, so we have decided to repeat much of
their work here.
For mathematical analysis, we disentangle two types of hitchhikers: (1) those that
reside in the Initial clone before the new driver arises (denoted p ), and (2) those
that arise and ﬁxate in the new driver clone as it Sweeps through the population (de-
noted p ). It is necessary to distinguish hitchhikers this way because only the initial
hitchhikers (pI) signiﬁcantly alter the ﬁxation probability f, while both types alter
the eﬀect size ∆N. The hitchhikers that accumulate during the sweep will generally
arise after the clone is of appreciable size; however, once the driver clone is of appre-
ciable size, it is exceedingly likely that it will ﬁxate so long as it remains the ﬁttest
59clone in the population.
Here, we consider only the average number of hitchhikers in a driver sweep (p 
and p ), rather than their entire distribution of quantities; estimates of the average
number of hitchhikers appear to explain dynamics reasonably well (ﬁrst shown in57
and also evident from our analysis’ good agreement with simulations in ﬁgure 4.1 on
page 46). Thus the probability that a new clone ﬁxates in the absence of Clonal Inter-
ference is (ﬁgure 4.4 on page 54):
d p    
s′
d p  
    s′
d p  
  s′
d p     sd   p sp (4.12)
The jump size ∆N becomes:
∆N′   N sd    p    p  sp  (4.13)
We can conclude our analysis of hitchhikers once we obtain p  and p . These
quantities were ﬁrst derived in57. We use their results (summarized below), along
with a minor necessary adjustment for populations when p is large, to complete our
analytical model of cancer progression.
For a new driver clone to take over the population and ﬁxate, it has been shown
that its ﬁtness must be greater than the ﬁttest class in the population57. This im-
poses a maximum on the number of initial hitchhikers p   
  that a successful driver
clone can have:
sd > p sp
p   
    ⌊sd=sp⌋
A clone that does not satisfy this constraint may proliferate for a while in the pop-
60ulation, but it will nevertheless be eventually out-competed by ﬁtter clones. When
the mean number of hitchhiking passengers (p) approaches this maximum, hitchhik-
ers dramatically reduce both f and ∆N, thus increasing N  to untenable sizes. This
occurs when:
p   p   
 
p=sp   ⌊sd=sp⌋
p   sd
(4.14)
Hence, our analysis suggests a limit on the maximum mutation rate that an adapt-
ing population can tolerate:  
p   sd. In simulations, we observe extinction slightly
above this threshold (ﬁgure 4.6 on page 64). This mechanism of collapse, where pop-
ulations go extinct by failing to acquire new advantageous mutations or adaptations,
diﬀers from the traditional model of mutational meltdown. In the traditional model,
advantageous mutations are generally ignored and meltdown occurs only because dele-
terious mutations accumulate too quickly. In our model, however, traditional muta-
tional meltdown is diﬃcult because populations also acquire advantageous mutations
faster as the mutation rate increases. Moreover, traditional meltdown occurs only
when the population size is small, making it impossible to occur in a large popula-
tion like cancer. Our discovery of a new mechanism of meltdown that is independent
of population size suggests that mutational meltdown may be induced via cancer ther-
apeutics.
The number of initial segregating passengers in a clone when a driver arises (pI)
can be obtained by considering, once again, the population at mutation selection bal-
ance, i.e. equation (4.7) on page 53. The average number of initial hitchhiking pas-
sengers is simply the average of the likelihood of a driver arising in each mutational
61class, conditional on the driver successfully sweeping through the population:
P p      
N Nnp pId p  
p     
N
∑pmax
I
pI   P p  d p  
   
N
∑pmax
I
pI  
e p
ppI
pI 
s′
d pI 
  s′
d pI 
(4.15)
Here, N  
∑pmax
I
pI   ′
d p   is a normalization constant.
The above solution fails when p is large. In this circumstance, the population is
far from mutation-selection balance. Rectifying the solution in this case is diﬃcult to
do precisely, however a simple correction to equation (4.15) can crudely ameliorate
the estimate. Because the assumption of mutation-selection balance fails only once
the expected number of passengers in the ﬁttest class becomes very small (Nnp    
Ne p    ), we propose that the actual ﬁttest surviving class in the population is the
ﬁrst class of passengers with an expected population size that is greater than the size
of ﬂuctuations in the population. Because the variance in a birth and death process is
the sum of the rates ( N in our model), the Fittest Surviving Class k    is:
k      minnp Nnp >
 
 N 
k      minnp e p
np
p =np  >
√
 
N 
The corrected distribution of p  then becomes:
p   
 
N
pmax
I ∑
pI  
P k   p    k    p d p  
This simple correction yields a ﬁnal solution for P       that agrees with simulations
well (ﬁgure 4.1 on page 46).
Lastly, the number of passengers that accumulate during the selective sweep (p )
62can be calculated using a recursive relationship. This relationship begins with the
probability of accumulating the maximum possible passengers during the sweep p   
 
57:
P p    p   
       
N2pmax
 
P p    k     
N2
k spP pS k   
  sp
p     
N2
∑pmax
I
pS   P p  
Where N   
∑pmax
pS   P pS  is a second normalization constant.
4.2 A critical mutation rate
By simulating cancer progression over a broad range of evolutionary parameters (ﬁg-
ure 4.1 on page 46), we observed another barrier to cancer: a critical mutation rate,
above which the probability of cancer is exceedingly low (ﬁgure 4.6 on the following
page). Through further analytical treatment (section 4.1.4 on page 57), we found that
this mutational barrier is created and determined by the load of segregating (unﬁxed)
passengers in the population.
The origin of a critical mutation rate can be understood by considering the number
of segregating passengers per cell, previously shown to be Poisson distributed with
mean p=sp, during mutation-selection balance53. The average ﬁtness reduction of a
cell due to this mutational load is then p. If this ﬁtness reduction exceeds the beneﬁt
of a new driver (p > sd), then drivers seldom ﬁxate57 (ﬁgure 4.4 on page 54). Hence,
cancer is extremely rare above the critical mutations rate     sd=Tp.
This analysis oﬀers a new mode by which mutational meltdown operates. Whereas
prior models of mutational meltdown consider deleterious mutations in isolation77,
we ﬁnd that mutational meltdown can occur when deleterious mutations inhibit the
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accumulation of advantageous mutations. Although previous research found that dele-
terious mutations can interfere with the ﬁxation of beneﬁcial alleles57,27, this phe-
nomenon has never been studied in the context of population survival.
When cancer progression is constrained to develop within a human lifetime, we
observe an optimum mutation rate for the probability of cancer (            
                               , ﬁgure 4.7), similar to experimentally-measured rates
in cancer of     7. Above     population meltdown is very common, while below
    progression is too slow.
4.3 Estimating the accumulation rate of passengers of varying ef-
fect
When deleterious mutations are drawn from a distribution of eﬀect sizes, estimating
their accumulation rate becomes more complicated and rigorous analytical treatment
of this situation has not been published to our knowledge. However, we will oﬀer an
approximate treatment in the limit of small  here. Figure 3.6 on page 31 demon-
strates that the population ﬁtness distributions remain constant between the ﬁxed-
65eﬀect and variable eﬀect models, with one caveat: the mean and variance of ﬁtness
relative to the ﬁttest class are now      p=   sp. Here,   sp represents the mean delete-
riousness of a passenger. While    is relatively large in ﬁgure 3.6 on page 31 (approx-
imately 50), this congruence should presumably hold so long as mutation eﬀect sizes
are generally smaller than the width of ﬁtness distribution. Obviously, if the vari-
ance of the distribution of ﬁtness were very large or undeﬁned (e.g. the variance of a
power-law distribution) this approximation may not hold. So long as this is not the
case, a new mutation, with its particular ﬁtness eﬀect   sp, has in the limit of small   , a
ﬁxation probability   of:
   
  sp
           sp N       
Here we used the ﬁxation probability in the weak mutation limit, but with population
size described by the size of the ﬁttest class.
For small   , it is clear that mutations in the deleterious tail, where   sp >   sp, will
ﬁxate in this model more often than in a model where all passengers exhibit an eﬀect
size of sp. Indeed, in the ﬁxed-eﬀect model, as mutations become more deleterious
they (1) are less likely to ﬁxate in a ﬁttest class of equivalent size, and (2) increase
the size of this ﬁttest class—further reducing their probability of ﬁxation. However in
a distribution of eﬀect sizes, a particularly-deleterious passenger only alters one half of
this equation: the probability of ﬁxating in the ﬁttest class, not the size of the ﬁttest
class. The size of the ﬁttest class is approximately deﬁned by the average passenger
(   sp) and not any particularly deleterious passenger   sp. Thus, the ﬁxation probability
of particularly-deleterious passengers declines less rapidly than one might expect from
the ﬁxed-eﬀect model (ﬁgure 3.6 on page 31).
For large   , accumulation rates are high and well approximated by a neutral model,
66so we expect at most a modest eﬀect of   sp relative to   sp on the rate of accumulation,
although we have and know of no existing theory to accurately describes this scenario.
Obviously, the ﬁxation rate should still exhibit some decline, if the ﬁtness distribution
has a long deleterious tail—as illustrated in ﬁgure 3.6 on page 31.
When considering the eﬀects of treatment strategies on passengers of varying eﬀect,
it is important to keep in mind that most of the passengers residing in a cancerous
cell have ﬁxated (there are about as many segregating passengers as ﬁxated passen-
gers, but the segregating passengers are often at low frequencies). Therefore, nearly
all of the eﬀects of increased selection against passengers will be on mutations that
cannot change in frequency in the population. For this reason, cancers grown under
previously estimated parameters with passengers drawn from an exponential distribu-
tion exhibited similar relapse rate as cancers grown under the ﬁxed eﬀect model.
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Genomic & Epidemiological evidence for
deleterious passengers
In the ﬁrst two chapters, we outlined a new evolutionary model that included delete-
rious passengers in a reasonable way, and then found that deleterious passengers can
accumulate and dramatically aﬀect progression. In the previous chapter, we inves-
tigated the mechanisms by which these passenger accumulated, which also speciﬁed
68the necessary ingredients for their accumulation and impact on progression. This re-
quired formulating a simpliﬁed mathematical description of progression. The mathe-
matical framework that emerged now provides us with a clearer understanding of our
model’s critical features and how it diﬀers from previous models of progression. This
now makes comparison to clinical, epidemiological, and genomic observations easier
because our solution is robust to evolutionary parameters and contains only two free
parameters (N  and sd), , exists in closed-form and is easily regressed onto data, is
mathematically precise, and easily intuited.
Thus we can now make several, bold, precise, measurable, and distinctive predic-
tions about existing cancers. Considering that we expected each individual passenger
to change the growth rate of a cancer cell by about one part in a thousand, this may
not have been expected a priori. This accomplishment is a testament to the utility of
population genetics theory.
Our model makes several testable predictions:
1. Accumulated passengers in cancer populations can be deleterious to cancer
cells;
2. The deleterious eﬀect of an individual passenger has little bearing on its likeli-
hood of accumulation;
3. Drivers that accumulate should have larger eﬀects on phenotype than passen-
gers;
4. A tug-of-war between drivers and passengers in individual cancers;
5. The presence of an eﬀective barrier to cancer that lesions seldom overcome,
696. which results in a broad distribution in the number of accumulated drivers and
passengers in tumors.
Recent cancer genomics and epidemiological data provide opportunities to test these
predictions. These data systematically supports the above predictions, suggesting that
our model is applicable to cancer progression. The data also provides an opportunity
to quantitatively measure the ﬁtness eﬀects of both drivers and passengers.
5.1 Passenger mutations observed in cancer exhibit signatures of dam-
aging phenotypes
First, we test whether nonsynonymous passengers found in cancer are damaging or
neutral to protein function using comparative genomics. Second, we test whether
selection acting against passengers is eﬀective at preventing ﬁxation or largely inef-
fective, as suggested by our simulations. We analyzed 116,977 cancer mutations cu-
rated by the Catalogue of Somatic Mutations in Cancer (COSMIC) and The Can-
cer Genome Atlas (TCGA). We the classiﬁed them as driver and passenger muta-
tion groups and then characterized their eﬀects using PolyPhen, a tool widely used
in population and medical genetics to predict the damaging eﬀect of missense mu-
tations14. Passengers were identiﬁed as missense mutations that show no recurrence
and aﬀect genes not listed in a census of possible cancer-causing genes (section A.1 on
page 105).
Our method of classifying drivers and passengers throughout this chapter was based
on previous techniques employed by the COSMIC and TCGA projects and fully de-
scribed in the Appendix (see chapter A on page 105). In short, we used the COMIC
methodology for pan-cancer analysis, and TCGA methodology for subtype-speciﬁc
70analysis. In general, their techniques are similar and both utilize the same sources of
information: primarily recurrence of mutations across tumor samples, but also both
leverage genomic and literature data for further reﬁnement.
The ∆PSIC metric of PolyPhen measures the degree of evolutionary conservation
of a mutated residue116 by calculating the negative log-likelihood of observing a spe-
ciﬁc mutation, given the evolutionary history of the protein. Speciﬁcally, a mutation
with a ∆PSIC of 1 is e (= 2.71...) times less likely to be observed than the wild-type
allele, as computed from a multiple alignment. Thus, a mutation with high ∆PSIC
is more likely to be under natural selection and aﬀecting to molecular function116, as
high values imply that the mutation disrupts a well-conserved residue. PolyPhen has
been extensively tested and benchmarked14.
Figure 5.1 on the following page presents this analysis for passengers, drivers, and
three reference datasets: (i) common human missense SNPs; (ii) simulated de novo
mutations (randomly generated using a cancer-speciﬁc three-parameter model; see
section A.1.1 on page 107); and (iii) damaging, pathogenic missense mutations caus-
ing human Mendelian diseases (from the Human Gene Mutation Database). As ex-
pected, common SNPs are benign and exhibit small ∆PSIC values, whereas disease-
causing mutations, with known damaging eﬀect, exhibit large ∆PSIC values. Driver
mutations exhibit similarly high values of ∆PSIC, signiﬁcantly greater than ran-
domly generated mutations, indicating that drivers tend to occur at well-conserved
loci. From a biochemical perspective, this result shows that, to activate an onco-
gene or to disable a tumor suppressor, the driver mutation must change a critical and
well-conserved residue, e.g. the GTP binding site of Ras or DNA binding domain of
p53. From an evolutionary perspective, the conservation of residues that promote
tumorigenesis when mutated suggests strong natural selection against the early de-
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usingthe∆PSIC scoreofPolyPhen,whichestimatesthedamagingeffectofanewmutation,givenknown
homologs;mutationswithhigh∆PSIC scoresaremostlikelydamaging
116. Passengershavelarge∆PSIC,
closetorandommutations,suggestingthattheyaredeleterious. Drivershaveverylarge∆PSIC,indicativeof
theirhighlynon-neutralphenotype. (B)Deleteriouspassengerphenotypeswereobservedinallsubsetsofpas-
sengersstudied,arguingthattheseresultscannotbeexplainedbyrecessivephenotypes,orlackofexpression,or
databasebiases.
velopment of cancer. The ability of ∆PSIC score to identify drivers as having highly
non-neutral phenotypes (i.e., damaging or altering molecular function) also validates
its use for characterizing somatic cancer mutations. The exceptionally high ∆PSIC
scores for these mutations are consistent with our third prediction that drivers must
be of strong eﬀect.
Most importantly, passenger mutations exhibit ∆PSIC values that are on average
much greater than neutral mutations (ﬁgure 5.1; p <     ); therefore, many passen-
gers aﬀect conserved residues and are likely damaging to protein function. This result
clearly demonstrates that passenger mutations are non-neutral. To ensure that our
set of putative passenger mutations was not contaminated by drivers, we increased
72our stringency of passenger classiﬁcation, but found no statistically signiﬁcant change
(p    :  ) in mean ∆PSIC*. Additional safeguards are explored below.
Passengers tended to exhibit ∆PSIC values that were much lower than drivers,
supporting the assumption of our evolutionary model that deleterious passengers are
generally much weaker than drivers (sp < sd). The ∆PSIC values of passengers are
close to, but lower than, values of randomly generated mutations (ﬁgure 5.1 on the
preceding page; p <      ), suggesting that many passenger mutations evade purify-
ing selection. Still, a statistically-signiﬁcant diﬀerence between these two sets demon-
strates slight negative selection against the most deleterious passengers. This compar-
ison of passengers and random mutations fully supports our model’s prediction that
selection against moderately deleterious passengers is largely ineﬀective in neoplastic
progression (ﬁgure 3.2 on page 24).
To rule out possible caveats where passengers have damaging eﬀects on protein
function but no eﬀect on the ﬁtness of cancer cells, we performed additional tests
in ﬁgure 5.1 on the preceding page. For example, passengers with deleterious scores
could aﬀect only genes that are functionally unimportant or not expressed in cancer
cells. Thus, we considered only passengers in essential and ubiquitously expressed
housekeeping genes, but still observe equally high ∆PSIC scores. This eliminates
the possibility that damaging passengers are not expressed or present in unimpor-
tant genes. Alternatively, perhaps only recessive heterozygous passengers exhibit high
∆PSIC scores; if so, cell ﬁtness would remain unchanged because the other allele
provides suﬃcient functionality. We observe equally high ∆PSIC scores for homozy-
*This stringent classiﬁcation required that all mutations be conﬁrmed by additional Sanger
sequencing and required that all passenger genes not only be non-drivers, but also exhibit a
ratio of non-synonymous to synonymous mutations consistent with purifying selection (sec-
tion 5.1.1 on the next page).
73gous passengers (which can arise via LOH events or chromosomal losses), refuting this
possibility. Collectively, our analyses show that signatures of damaging mutations are
ubiquitous in known passengers and likely aﬀect the ﬁtness of cancerous cells.
5.1.1 Passengers are very rarely eliminated by natural selection
We assayed for signatures of selection in driver and passenger genes by comparing
the observed ratio ! of nonsynonymous to synonymous mutations to the predicted
ratio using a random model of mutations (section A.1.1 on page 107, ﬁgure 5.2 on the
following page). Operationally, we deﬁned the ratio of nonsynonymous to synonymous
mutations as follows:
!  
!        
!        
 
O             =O          
E             =E          
Here O represents the observed mutations within a gene of interest (synonymous or
nonsynonymous) and E represents the expected mutations in that gene. Expectations
were based on a 3-parameter random null-model of mutagenesis, where mutations in
genes experience no selection (section A.1.1 on page 107). We generated expected his-
tograms, by binomially sampling nonsynonymous and synonymous mutations from
each gene using E             = E                E            as the probability of a
nonsynonymous mutations in the gene. The number of trials in each gene sampling
was constrained to equal the number of observed mutations and trials with no syn-
onymous mutations (undeﬁned !) were discarded from the null distribution—just as
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genes with no observed synonymous mutations were discarded from the observed his-
togram.
This distribution reaﬃrmed COSMIC’s driver and passenger classiﬁcations. Genes
with ! <   likely experience purifying selection and these genes were generally classi-
ﬁed as passengers by COSMIC. Conversely, genes with ! >   likely experience posi-
tive selection and were nearly all classiﬁed as drivers by COSMIC. Most importantly,
the shape of this distribution corroborates the narrative of a few strong drivers over-
75laid with copious passengers experiencing nearly undetectable negative selection that
we observe in both our modeling and ∆PSIC analysis: A total of 94% of genes had
an observed ! <  , and their occurrence was only very moderately enriched relative
to our neutral model—on the fringe of statistical signiﬁcance: p    :   —and not
nearly as pronounced as the signal for drivers. Nevertheless, the true extent of purify-
ing selection in cancer may be greater than suggested by this analysis of the COSMIC
database. Consider that some publications do not report synonymous mutations and
consider that putative passengers in ﬁgure 5.2 on the previous page may actually be
an amalgam of genomic loci under negative selection mixed with loci under positive
selection. These two complications would cause the observed degree of purifying selec-
tion to be less than the extent of purifying selection in reality.
The rare driver genes, with ! >  , often exhibited extreme nonsynonymous sub-
stitution rates vastly greater than expected from a neutral model of evolution: ! of
KRAS, TP53, BRAF, and PTEN were all greater than 40. This supports the predic-
tion of our model that the commonly accumulated drivers in cancer are of very large
beneﬁcial eﬀect. While driver of moderate beneﬁt may exist in the population and
accumulate with frequencies slightly above the neutral rate, we ﬁnd that the most
studied drivers are very powerful.
Although this genomic analysis of passenger mutations focused on missense substi-
tutions, our model is generalizable to all inheritable (epi)genetic alterations, including
those that are present at low frequency in the cancer population. Indeed, the length
distribution of somatic copy number alterations (SCNAs) in cancer suggests these al-
terations are under purifying selection as well38. Hence, the total load of accumulated
deleterious passengers in cancer may be greater than that estimated from single nu-
cleotide mutations detected in genome sequencing.
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5.2 Evidence of a critical barrier in cancer age-incidence curves
Figure 5.3 presents the incidence rate of breast cancer versus age55 alongside the pre-
dictions from our model and a classic driver-only model (section A.3 on page 110).
The incidence rate was calculated by assuming that precancerous lesions arise with
a constant rate r beginning at birth. Lesions then progress to cancer in time  with
probability P  , determined from simulations. The age-incidence rate I t  is then
the convolution of P   with the lesion initiation rate r. Since many lesions never
progress and go extinct in our model, the incidence rate saturates at old-age: I     
r
  ∫
 
P   d  rP , where P  is the probability that a lesion ever progresses to cancer
(see section A.2.1 on page 110 for details).
Observed age-incidence rates saturate with age, allowing us to roughly estimate
the eﬃciency of cancer progression. We estimate that the rate of lesion formation in
77breast cancer r is      per year, deducible in two ways: by multiplying the num-
ber of human breast epithelial stem cells by their rate of mutation into a lesion (sec-
tion A.2.1 on page 110), or by considering the number of lesions observed in normal
breasts98. By comparing this limit (r            ) to the maximum observed breast
cancer incidence rate I                           , we ﬁnd that P        , or
only  0.1% of lesions ever progress. Conversely, in a driver-only model (section A.3
on page 110), every lesion eventually progresses to cancer after suﬃcient time (i.e.
P     ) and incidence rates plateau only if the lesion formation rate is unrealistically
low (0.01 per year). Good agreement between age-incidence data and our model is ob-
tained for sd    :     : , and N =N  is chosen such that P        . This suggests
that cancer begins at a population size far below N , where drivers are most often
overpowered by passengers.
Likewise, ﬁgure 5.4 on the next page shows that most other cancer subtypes (84%)
plateau at old age, indicating that ineﬃcient progression is common. These ﬁndings
are consistent with medical observations that very few lesions ever progress to can-
cer13,118. Like our model, these studies ﬁnd that most cancers regress to undetectable
size. Collectively, these results suggest that most cancers experience a barrier to pro-
gression that we believe is caused by passengers. Progression is ineﬃcient and age-
incidence curves are most consistent with our model for large sd.
5.3 A wide and assymetric distribution of mutation totals suggests
sd is large
We looked at Somatic Nonsynonymous Mutations (SNMs) and Somatic Copy-Number
Alterations (SCNAs) from over 700 individual cancer-normal sample pairs obtain
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haveﬂattercurves,suggestingthattheyneedfewerdriversforcarcinogenesis. Onlycolorectalcancerdoesnot
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79in breast115, colon21, lung28, and skin10 cancer (table 1.1 on page 4) to interrogate
properties of drivers and passengers in these tumors that might support or refute our
theory.
Analyzing SNMs and SCNAs separately and in aggregation yielded similar results
(ﬁgure 5.8 on page 86, table A.1 on page 116). Figure 5.5 on the next page shows a
wide and asymmetric distribution of the total number of SNMs in breast cancer. Our
model predicts a similarly wide distribution of total SNMs due to the stochastic pe-
riod of time that cancers linger at the critical population size N  while accumulating
mutations. To compare these data with various models of progression, we normalized
the total number of mutations by their median (27), as several evolutionary parame-
ters and sequencing decisions can alter these distributions by a multiplicative factor
(section A.2 on page 108).
Our model agrees with the data when the eﬀect size of drivers is large (sd    : ).
In contrast, a traditional 5-driver model (section A.3 on page 110, ﬁgure 5.6 on page 82),
which neglects deleterious passengers (and, thus, a critical barrier), yields a narrower,
less-skewed distribution than observed. The critical barrier in our model increases the
variance and skew of the expected distribution because populations can linger around
N  for a highly variable period of evolutionary time (all while acquiring additional
drivers and passengers). The traditional model of cancer presumes progression is
more-or-less a methodical march towards cancer where every driver is an irreversible
step closer to carcinogenesis. No declines in population size, due to passenger accumu-
lation are possible. As such, the variance in progression time and resulting mutation
totals are comparatively smaller.
Overall, our model agrees with the 11 most sequenced cancer subtypes with 100 or
more sequenced tumors72. Our ﬁt was best when sd    :     :  (ﬁgure 5.6 on the pre-
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82Table5.1: Kolmogorov-Smirnovgoodnessofﬁtestimatesofsd (ourmodel)andk (traditionalmodel)fromthe
most-sequencedcancersubtypes. Weselectedourbestﬁttingmodel,andthebestﬁttingtraditionalmodel
(largestDstatistic)usingaKolmogorov-Smirnovgoodnessofﬁttestanddisplayedthebestﬁttingestimatesof
sd ork alongsidetheirqualityofﬁt.
Our model Traditional model
Tissue N sd  p-value* k  p-value*
Acute myeloid leukemia 132 0.8 0.802 1 0.072
Breast 120 0.6 0.860 1 0.045
Colorectal 230 0.2 0.956 2 0.011
Glioblastoma multiforme 219 0.1 0.070 3 0.187
Head and neck 178 0.8 0.120 1 0.077
Kidney clear cell 214 0.2 0.485 2 0.066
Lung adenocarcinoma 333 0.8  :          1  :         
Lung squamous cell 178 0.4 0.752 1  :         
Melanoma 121 0.8 0.267 1 0.073
Ovarian 385 0.4 0.833 1  :         
Prostate 221 0.4 0.134 1 0.018
*2-sided probability that the observed and expected distributions are identical.
  Optimal theoretical ﬁt to observed data for sd     :  ; : ; : ; : ; : ; :  
  See section A.3 on page 110 for our M-L Estimator of this quantity.
vious page). These estimates agree with sd    :      :   that were measured experi-
mentally as growth rate changes of mouse intestinal stem cells upon mutations in p53,
APC or k-RAS119 (table 5.1). These experimental measurements and our estimates
are also considerably larger than previous theoretical estimates of sd    :   15, where
cancer progression was modeled as an exponential growth unaﬀected by passengers.
A driver-only model ﬁts SNM distributions poorly and suggests that just 1-2 drivers
are needed for cancer (table 5.1), which is inconsistent with known biology. Taken
together, cancer genomics data and recent direct ﬁtness measurements in mice119
strongly support our model and refute the driver-only model.
835.4 Tug-of-war between drivers and passengers is manifested by their
positive linear relationship in tumor samples
We then compared the number of drivers and the number of passengers observed in
individual cancer samples to our model. Lesions that linger around N  in our model
acquire additional passengers and additional counterbalancing drivers, while lesions
that progress quickly acquire fewer of each. This predicts a linear relationship: nd  
sp=sd   np            (chapter 4 on page 41), where the slope provides an estimate of
sp=sd . We indeed observe a positive linear relationship between nd and np in all tu-
mors studied (ﬁgure 5.7 on the following page, table A.1 on page 116, p <  :  –    ).
Linearity was conﬁrmed by regressing the aggregated data in log-log axes (ﬁgure 5.7
on the following page), which yielded nd   n :  
p , consistent with nd   np. Regressing
nd on np, and using     bootstrapped samples to estimate the conﬁdence, we obtain
an sp=sd    :   – :   (ﬁgure 5.7 on the next page). Using our estimate sd    : – : 
we obtain damaging eﬀect of a passenger mutation sp            –     . These es-
timates are consistent with the eﬀects of germ-line SNMs in humans, where 64% of
mutations decrease ﬁtness by     –    14. In summary, this analysis shows that pas-
sengers are indeed deleterious and        weaker than drivers.
We considered and refuted several alternative explanations for the observed positive
linear relationship between drivers and passengers. First, variation in the tumor stage
or the rate/mechanism of mutagenesis cannot explain the observed relationship (ta-
ble A.1 on page 116). Second, SCNAs and SNMs are uncorrelated, so the relationship
could not results from their diﬀering eﬀect sizes (table A.1 on page 116, ﬁgure 5.8 on
page 86). As the data disagrees with these alternate hypotheses, we conclude that
cancer indeed proceeds as a tug-of-war between drivers and passengers.
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86Collectively, these results strongly support our theory that deleterious passengers
accumulate in cancer, evade natural selection, and present a barrier to progression
that lesions stochastically overcome. The data suggests that these dynamics are pos-
sible because drivers are rare strong-eﬀect mutations and alterations, while passengers
are common, yet mildly deleterious.
876
Clinical outcomes & passenger therapies
6.1 Accumulated Passenger Mutations Can Be Exploited for Can-
cer Treatment
Using our evolutionary model, we probed how cancers that accumulated passenger
alterations respond to passenger-centric treatments. We tested two strategies: (i) in-
creasing the overall mutation rate (), thus increasing the rate of passenger accumula-
88A
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Figure6.1: Deleteriouspassengerscanbeexploitedfortreatment. (A)Cancersgrownto  6 cellsaretreated
byincreasingthemutationrate(green)ordeleteriouseffectofpassengers(magenta). Bothstrategiesleadto
reductionincancersize. (B)Muchsmallerincreaseofthedeleteriouseffectofpassengersissufﬁcienttoprevent
5-yearrelapse.
tion, and (ii) magnifying the deleterious eﬀect of passengers (sp), as described below.
Figure 6.1 demonstrates that both strategies reduce cancer size; however, mutagenic
strategies require more severe increases (￿50-fold) in the mutation rate to succeed (ﬁg-
ure 6.1), whereas ﬁvefold magniﬁcations of passengers’ deleterious eﬀect suﬃce. Even
with large mutation rate increases, the probability of 5-year relapse following treat-
ment initiation is considerable (ﬁgure 6.1). This behavior resembles patient responses
to existing chemotherapeutic agents that elevate mutation rates.
In practice, increasing the deleterious eﬀect of passengers, both mutations and
89chromosomal alterations108, could be achieved by inhibiting cellular mechanisms that
buﬀer against the eﬀects of mutations or incorrect protein dosage41. Hence, the dele-
terious eﬀect of passengers could be increased by targeting chaperones, proteasomes,
or other components of UPR pathways25; or by elevating ER stress26; or by stimu-
lating protein misfolding using hyperthermia125. These passenger-mediated therapies
should speciﬁcally aﬀect cancer cells because somatic mutations are generally rarer in
normal tissues22. For example, a recent study of clonal mosaicism in human brains
found only 1.5 SCNAs per adult sample112, whereas a recent pan-cancer survey found
42 SCNAs per cancer11.
Several experiments support this strategy of exacerbating passengers’ eﬀect. First,
chaperones are widely expressed in cancer, indicative of poor prognosis105, and their
inhibition (or proteasome inhibition) exhibits antitumor activity25. Though other
speciﬁc roles of chaperons and proteasomes in cancer were proposed, our framework
suggests that cancers buﬀer against the eﬀects of passenger alterations using UPR
machinery. In our paradigm, inhibiting the UPR unleashes the eﬀects of accumulated
passengers. Recent discoveries that aneuploidy and chromosomal imbalance lead to
proteotoxic stress108 and a dependence on the UPR for survival26.
6.2 The adaptive barrier and critical mutation rate explain cancer
treatment outcomes
Chemotherapy and radiation are valued for their ability to kill rapidly dividing cells;
however, our model shows that the elevation of mutation rates (including SCNAs and
aneuploidy) by these therapies dramatically aﬀects cancer survival. We use the phase
diagrams from ﬁgure 4.1 on page 46 to rationalize outcomes of these and other treat-
90ments.
In ﬁgure 6.2 on the following page, we present evolutionary paths of cancers—
from hyperplasia, to cancer, to treatment, and relapse or remission—on top of the
phase diagrams described above. Treatments succeed if they push cancer into the
non-adaptive regime where the probability of growth is low, and fail if they do not.
Our model suggests that chemotherapy succeeds, in part, because it moves cancers
across the mutational threshold  . Above this threshold, drivers seldom overpower
the load of segregating passengers, making re-adaptation diﬃcult. Driver-targeted
therapies (that eliminate an oncogene’s beneﬁt) must bring N < N  to succeed.
Cancers with higher loads of mutations/alterations are closer to the critical muta-
tion rate and should be most susceptible to mutagenic meltdown. Several recent stud-
ies12,23,121 found that patient survival from breast (all subtypes) and ovarian cancer
was greatest when tumors harbored exceptionally high levels of chromosomal alter-
ations. These ﬁndings are paradoxical for all previous models of cancer12, where a
greater mutation rate always accelerates cancer, yet fully consistent with our model
(ﬁgure 6.2 on the next page).
Treatments exploiting cancer’s load of deleterious passengers remain unexplored.
Figure 6.2 on the following page shows that a relatively mild 3-5 fold increase of the
deleterious eﬀect of passengers sp causes complete remission. Increasing sp is doubly
eﬀective because it exacerbates accumulated passengers and slows down future adap-
tation. Below we discuss possible treatment strategies that would increase sp.
We ﬁnd that simultaneously increasing cancer’s mutation rate and the ﬁtness cost
of passengers is most eﬀective: more eﬀective than would be expected from adding
together their individual eﬀects (ﬁgure 6.3 on page 93). Hence, combinations of mu-
tagenic chemotherapy alongside treatments elevating the cost of passengers may be
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Figure6.2: Mappingandinterpretingtreatmentoutcomes. (A)(Top)Anadaptedpopulation(cancer)canbere-
vertedtoextinctionbyincreasingthemutationrate(mutagenicchemotherapy)orbydecreasingthepopulation
size(e.g. surgeryorcytotoxicchemotherapy). However,relapseispossible. (Bottom)Ourphasediagramsexplain
therapeuticoutcomes: therapiesthatalterevolutionaryparametersenoughtopushitoutsideoftheadaptive
regimecausecontinuedpopulationcollapse;thosethatdonotpushapopulationoutsideoftheadaptiveregime
re-adaptandrelapse. (B)(Top)Cancerswithintermediatemutationalloadsarethemostaggressive
12,121,while
patientswithveryhighlevelofchromosomalinstabilityaremosteffectivelytreated. (Bottom)Thisresultis
wellexplainedbyourphasediagrams,wherecancerwithveryhighmutationratesaresusceptibletomutational
meltdown. Yetthisresultisparadoxicalforallpreviousevolutionarymodelsofcancer. Inthisdiagram,weas-
sumetraditionaltherapiesdecreasepopulationsizeandmildyincreasethemutationrate. (C)Arelatively-mild
three-foldincreaseintheeffectofpassengermutations(sp)leadstorapidpopulationmeltdownbelowN ,thus
withoutrelapse.
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Figure6.3: Combinationtreatmentsthatincreasemutationrateandselectionagainstpassengersworkbest.
(A)Usingtheanalyticaltheorydescribeinchapter4onpage41andﬁgure4.1onpage46,weplottedthecritical
populationsizeN  acrossevolutionaryparametersasacontourplot. Optimaltherapy,fromanevolutionary
perspective,shouldincreaseN  alongitsgradientofsteepestascent(bluelines). Fromthis3-Dimensionalper-
spectivetheinterplaybetweenandsp isevident. Forcancerswithlowmutationrates,onlyweakpassengers
(lowsp)canﬁxate. Thus,thesecancersshouldberelativelyimmunetodrugsthatincreasesp. Cancerswithhigh
mutationratesﬁxateallpassengers,makingpassenger-targetedtherapieshighlyeffective. Atintermediatemu-
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ulations,wetestedourpredictionthatthegradientofsteepestascentisoptimalforthemagenta-coloredvector
inA.50cancerswith      8;sp    :   grownto  6 cellsweretreatedwithcombinationsofmutagenic
andsp increasingtherapy. Indeed,moderateincreasesinbothparametersweremoreeffectivethanwouldbe
expectedfromthelonetreatments,thusconﬁrmingourprediction. Theseresultsunderscoretheimportanceof
combinatorialtherapiesandevolutionarymodelingforcancertreatment.
most eﬀective; these therapies should also synergize with driver-targeted therapies.
93In [unadapted] condition there is no place for
industry, because the fruit thereof is uncertain,
and consequently, not culture of the earth, no
navigation, nor the use of commodities that
may be imported by sea, no commodious build-
ing, no instruments of moving and removing
such things as require much force, no knowledge
of the face of the earth, no account of time,
no arts, no letters, no society, and which is
worst of all, continual fear and danger of violent
death, and the life of man, solitary, poor, nasty,
brutish, and short.
Thomas Hobbes 7
Discussion and Future Directions
7.1 Conclusions
Cancer research has focused primarily on driver alterations with little attention to the
overwhelming majority of potentially harmful passenger alterations that arise along
the way. This “dark matter” of cancer genomes has not yet been previously explored
in a systematic way. We developed an evolutionary model of cancer progression that
94Table7.1: Thedeleteriouspassengermodelreproducesmanypropertiesofcancer. Manyoftheabovephe-
nomenawouldnotbeobservedinourmodelwithouttheinclusionofdeleteriouspassengers. Noneoftheabove
phenomenawerepre-programmedintothemodelofneoplasticgrowth(i.e. populationsizewasnotﬁxed,nor
wasthenumberofmutations).
Experimental
Phenomena Observed in our model Observation
Clonal expansion, delayed growth, and extinction 2,54
Most lesions spontaneously regress 13,118
More mutations accumulate with high mutation rate 75
           deleterious mutations accumulate 101,102
Signiﬁcant heterogeneity in tumors cells, yet driver mutations
are often clonal 74,126,19
Mutagenic therapies often relapse after a period of remission 110
The most mutagenic tumors respond best to traditional therapies 12,23,121
clearly demonstrates that deleterious passengers can accumulate in cancer, while our
genomic analysis conﬁrms that passengers presented in sequenced cancers have dam-
aging phenotypes. Importantly, when cancer is modeled as balance between drivers
and deleterious passengers, many observed phenomena in cancer are reproduced, in-
cluding (i) slow initial and rapid late growth; (ii) a critical cancer size for dormancy
or spontaneous regression; (iii) short-term response to mutagenic therapies; and (iv)
substantial stochasticity of dynamics and (v) ineﬃciency in progression (table 7.1).
These phenomena were not preprogrammed into the model, suggesting that the dele-
terious eﬀect of passengers explains many properties of cancers.
In our evolutionary model of rapid adaptation, rare strongly-advantageous driver
mutations accumulate amid frequent mildly-deleterious passenger mutations. In this
tug-of-war process, populations either succeed and adapt, or fail and go extinct. Sim-
ulations and theory identify two regimes of dynamics: one where populations almost
always adapt, and another where they almost always fail. We also found a critical
mutation rate, above which populations quickly meltdown.
95This general framework for adaptive asexual populations eﬀectively characterizes
the observed dynamics of cancer progression and therapeutic responses. We show
that the late onset of cancer, evident in age-incidence curves, can be explained by
a passenger-generated barrier to cancer, and does not require more complex models
of cancer progression (e.g. a speciﬁc order of mutations, or multi-hit model, or vari-
able mutation rate). We also considered a commonly used “two-hit model”, where the
ﬁrst driver confers no ﬁtness beneﬁt, while two drivers confer a strong cumulative ef-
fect. This two-hit model also exhibits a barrier to cancer and behaves similarly to our
model, yet with an eﬀectively larger N  and sd.
Our framework suggests that most normal tissues reside in a regime where cancer
progression is exceedingly rare. Most lesions fail to overcome the adaptive barrier at
N . This implies that observed tumors acquired drivers faster than a mean trajectory,
which may be testable via phylogenetic analysis.
Clinical cancers, on the contrary, reside above the adaptive barrier in a rapidly
adapting state. Successful therapies must push a cancer below this adaptive barrier
N  to succeed. In our framework, this entails moving populations below N  or in-
creasing mutation rate above the critical value  . A broad range of cancer data al-
lowed us to thoroughly test the applicability of these barriers.
We tested our model and estimated its parameters using age-incidence curves, can-
cer exome sequences from  1,000 tumors in four cancer subtypes, and data on clinical
outcomes. Age-incidence curves support our hypothesis that nearly all lesions fail to
progress and allowed us to estimate the ﬁtness beneﬁt of a driver as sd    : – :  — in
good agreement with direct experimental measurements119.
We found that individual SNM passengers exhibit signatures of damaging muta-
tions, and thus likely aﬀect the ﬁtness of cancerous cells. The length distribution
96of SCNAs in cancer suggests that these alterations are also under purifying selec-
tion as well38. Deleterious passengers could result from any inheritable change in
cell state, e.g. stable changes in cell signaling, or epigenetic modiﬁcations. Genomics
data also aﬃrmed that passengers are deleterious with an sp    
   sd, yielding sp  
         –     , have a damaging eﬀect    -times smaller that the eﬀect of driver, but
are a hundred times more numerous than drivers. Taken together, these data support
the notion of a tug-of-war between rare large-eﬀect drivers, verses frequent mildly-
deleterious passengers.
We focused on the evolution of cancer, but our model should generalize to other
adaptive asexual processes. Consider a small population entering a new environment.
Fluctuations in its size often lead to its extinction. Occasionally, however, the popu-
lation may acquire several new highly-advantageous traits for this new environment,
allowing it to rapidly expand its size and avert extinction. Both its evolutionary pa-
rameters48 and behavior9 mirror our model. Our mathematical framework further
explains why these populations sometimes adapt, yet often fail.
7.2 Important considerations for future evolutionary models of can-
cer progression
Our simple model captured many of the phenomena of carcinogenesis and treatment
without be preprogrammed to do so. As such, we expect the to be very instructive for
a large array of future work. However, there are several evolutionary questions that I
believe are particularly pressing given our recent ﬁndings.
977.2.1 Modeling the gain and/or loss of a mutator phenotype
We assumed that the mutation rate is constant in our evolving population. Often an
enhanced mutation rate in cancer cells is a result of driver mutations that increase
cell ﬁtness by eliminating cell-cycle checkpoints, which also ensure that DNA is faith-
fully repaired. However, an increased mutation rate can also be the direct result of
mutations in DNA repair genes75. These mutator phenotypes are believed to be most
beneﬁcial if they arise early96, but, if mildly-deleterious passengers are considered,
may become disadvantageous in later stages of cancer progression.
Our analysis agrees with the current belief that a mutator phenotype is most ben-
eﬁcial early in tumor progression. Early on, many driver mutations are accessible
and the rate of progression is limited by the rate at which drivers mutate. Because
mildly-deleterious passengers are not readily selected against, increases in the muta-
tion rate should not increase their probability of ﬁxation. However, later in tumor
progression, a mutator phenotype should become disadvantageous to the population
as a whole. The accumulation of drivers should become limited by clonal interference
(section 4.1.4 on page 57), rather than being limited by accessibility of drivers and
the mutation rate. With a larger population size, natural selection should be capa-
ble of weeding-out deleterious passengers, but only if the mutation rate is moderate.
Hence, decreases in the mutation rate can decrease vp when the population size is
large. Lastly, as the population begins to adapt to its new microenvironment (evident
by its increase in population size) the average beneﬁt of new drivers should decline.
Because,     sd (section 4.2 on page 63), this should lead to a lower threshold for
mutational meltdown.
Thus, decreases in the mutation rate in the later stages of cancer progression should
98be beneﬁcial for the population as a whole, if not necessary. Yet no thorough investi-
gation of the selective pressures for or against a mutator phenotype in cancer have
been performed. These forces should depend critically on the extent of deleterious
passengers in the population. In natural populations, theoretical work suggests that
complete genetic linkage (i.e. asexual population dynamics, as we model in cancer
evolution) can result in mutator phenotypes being beneﬁcial to individuals at nearly
any mutation rate. In fact, the genetic linkage between mutator phenotypes and the
beneﬁcial drivers they may create can lead to runaway mutation rates that harm the
total ﬁtness of the population42. Whether this applies to cancer is unknown. If a run-
away mutation rate can be fostered, or even selected for, then new therapeutic strate-
gies may be possible.
7.2.2 Understanding the spatial structure of cancer
As with many evolutionary models, we assumed that our population was ‘well-mixed’,
i.e. each individual was equally able to reproduce (genetics notwithstanding) at any
given time, regardless of its position in space. In reality, tumors exist in a thee-dimensional
environment, which experiences strong hydrostatic pressures, pH and oxygen gradi-
ents, contact inhibition, and paracrine signaling factors. In general, spatial segrega-
tion and environmental constraints have a tendency to undermine natural selection
and increase the eﬀects of genetic drift. Unlike some confounding factors in evolu-
tionary theory, these changes generally cannot be subsumed into a alteration of the
eﬀective size, as spatial constraints aﬀect each evolutionary metric diﬀerently. Thus, a
careful evolutionary investigation of these spatial constraints would be very informa-
tive.
Spatial structure in tumors has been shown to prolong the waiting time to can-
99cer81. As many precancerous populations do not progress to cancer within a human
lifetime in well-mixed populations, the greater time constraint that spatial segregation
imposes on cancer progression should encourage an even higher mutation rate, and
necessitate that drivers be even more advantageous in cancer. How spatial structure
aﬀects the accumulation of mildly deleterious passengers remains unexplored. In all
likelihood, spatial structure should continue to diminish the eﬀectiveness of natural
selection and increase the ﬁxation probability of moderately deleterious passengers.
Spatial structure in tumors has also been shown to increase the degree of genetic
diversity45. In general, the size of ﬂuctuations of segregating alleles diminishes in spa-
tially segregated populations. This increases their resident time in the population,
and thus the number of segregating alleles at any one time. Understanding the de-
gree of genetic diversity and how this diversity is modiﬁed by mutations with a mildly
deleterious eﬀect is critical to understanding the evolution of resistance in cancer.
7.3 Implications for cancer therapy and targeting deleterious pas-
sengers
Clinicians could exploit deleterious passengers by either increasing the mutation/alteration
rate in cancers with already high mutation rates, or by increasing the deleterious ef-
fect of passengers. Clinical data indeed show that cancers with a higher load of chro-
mosomal alterations, closer to  , respond better to treatments12,23,121. PARP in-
hibitors, which increase DNA damage in BRCA1/2–positive tumors, may already be
curing patients by inducing mutational meltdown73.
1007.3.1 Cancer’s mutation rate as a biomarker for mutagenic therapy
A cancer’s elevated mutation rate is a double-edged sword, it increases the likelihood
of new drivers and mutations that might lead to drug resistance, but also introduce
mutations that are harmful to the cancer cells. Our theory argues that clinicians
should try to keep cancer’s away from the optimal mutation rate    . Hence, patients
with CIN or MIN might be best suited for mutagenic chemotherapies and radiation.
Likewise, patients with a low or moderate mutation rate should not be treated with
these therapies—they may make the tumor more aggressive. Fortuitously, these pa-
tients are, instead, ideal candidates for driver-targeted therapies, as their tumors are
the least likely to evolve resistance.
We also argue that an increase in the mutation rate should increase the variation in
ﬁtness and phenotypes of a cancerous population. This theory can be tested experi-
mentally, by comparing the morphology of cancer cells with a mutator phenotype to
those without a mutator phenotype. We predict that cells with a mutator phenotype
will exhibit greater morphological variability. This morphological variability may be
exploitable by immunotherapies.
Morphological variability and genetic variability within a cancer population should
be important biomarkers for inferring a patient’s response to mutagenic therapies.
Consider that a population’s variation in ﬁtness is proportional to p (ﬁgure 3.6 on
page 31)*. This implies that, if this standing genetic variation is large, then either
the mutation rate is large, or the selection against passengers is small (and thus pas-
sengers are segregating in the population for a longer period of time). Tumors with
a large degree of genetic variably, but low overall mutation rate can only exist in our
*This result also follows from Fischer’s Fundamental Theory of Natural Selection and
should hold even if many of the assumptions of our model are wrong
101model if they have found a way to reduce the deleteriousness of passengers, perhaps
by mutations in UPR pathways or the Major Histocompatibility Complex. Conse-
quently, these tumors will theoretically be most resistant to mutagenic chemotherapy
and thermotherapy, but most susceptible to chaperone and proteasome inhibitors.
7.3.2 Exacerbating passenger’s deleterious effects
Passenger mutations and alterations can be deleterious by gain-of-function toxicity via
proteotoxic/misfolding stress108,59, or by eliciting an immune response to mutated epi-
topes120. Their damage to cancer cells could be magniﬁed by (i) inhibiting unfolded
protein response (UPR) pathways and proteasomes108, (ii) hyperthermia that further
destabilizes mutated proteins and clogs UPR pathways103, or (iii) by activating an
immune response106. Intriguingly, all these strategies are in clinical trials, yet none
are believed to work by exacerbating passengers’ deleterious eﬀects. We oﬀer an al-
ternative explanation for their eﬃcacy and suggest that these therapies will be most
eﬀective if used collectively and in cancers with many passengers.
One of the major limitations of driver-targeted therapies is that they can be de-
feated by a cancer’s ability to rapidly evolve resistance by acquiring new mutations.
Our approach, of increasing the deleterious eﬀects of passengers, is diﬀerent as it
targets not only existing cancer cells, but also cancer’s ability to accumulate new
mutations—eﬀectively decreasing its evolvability. Thus, these therapies should work
well in combination with driver-targeted therapies.
It is important to consider that therapies that exacerbate deleterious passengers
in cancer could also exacerbate the deleterious eﬀects of mutations in the germ-line
or somatic mutations outside of cancers. While there is evidence that these muta-
tional loads are low78, this possibility should be investigated further. Patients with
102lower levels of protein-destabilizing germ-line mutations would be ideal candidates
for passenger-targeted therapies. Like many cancer therapies, keeping the therapeutic
drugs localized to the tumor site would be beneﬁcial.
7.4 Deleterious passengers may explain metastatic inefficiency
The transformation of cancer from localized to metastatic is a highly lethal and poorly
understood process. Evolutionary dynamics drive the primary tumor population, but
also are important in the selection of successful metastases. The process of metastasis
is highly ineﬃcient, yet is the eventual endpoint of most cancers and usually results
in patient death. While we yet lack the ability to predict where a given patient’s can-
cer will metastasize, patterns of metastasis are observed and well documented for each
diﬀerent type of primary tumor. This suggests that while the process is random, it
is driven by deterministic factors that we do not yet fully understand. The popular
‘seed and soil’ hypothesis states that not only are primary tumor— the‘seed’—factors
important, but the ﬁnal stromal site of arrest—the ‘soil’—also plays a critical role.
Metastasis is a highly ineﬃcient process; estimates of hematogenous shedding of
tumors cells are as high as     cells per gram of tissue17, yet the incidence of clini-
cally viable sites of metastasis does not reﬂect this number. There are many instances
where patients will have evidence of tumor cells ﬂowing in their blood without any
evidence of any metastatic disease89. There is also evidence of patients with small,
subclinical deposits of tumor cells in their marrow space (and assumedly other unas-
sayed spaces) who never go on to develop overt clinical metastasis35. Indeed, in most
cancers, these patients are not considered to have metastatic disease.
Deleterious passengers may explain ineﬃcient metastatic ineﬃciency, just as they
103have explained ineﬃcient tumor progression. Indeed, metastases harbor more pas-
sengers than the primary tumor and experience a population bottleneck during dis-
semination that may push populations below the critical population size N  that we
identiﬁed in primary tumor progression. If passengers are partially responsible for
metastatic ineﬃciency, then targeting them would have the added beneﬁt of safe-
guarding against metastatic disease. Future models of this complicated progression
should prove useful to clinicians.
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Methodology
A.1 Analysis of somatic mutations in cancer for ∆PSIC analysis and
for signatures of positive and negative selection
All cancer mutations were collected from the ongoing COSMIC database at http:
//www.sanger.ac.uk/genetics/CGP/cosmic/36. COSMIC and TCGA, along with
other cancer genomics consortia, have focused on identifying driver mutations (i.e.
105distinguishing drivers from passengers) by their recurrence in multiple patients or
samples36. Using COSMIC, we identiﬁed 4,195 missense passenger mutations (non-
synonymous, amino acid changes) from a total of 116,977 mutations. We deﬁned
a mutation as a passenger if it arose in a gene not listed in the census of possible
cancer-causing genes39. These 4,195 ‘passenger’ mutations show no recurrence and are
dispersed across 3,172 genes, further supporting their classiﬁcation as passengers. We
then contrasted these mutations with driver mutations and three reference datasets:
1. benign, common human non-synonymous SNPs;
2. simulated de novo mutations (randomly generated using a cancer-speciﬁc 3-
parameter model described in detail below); and
3. damaging, pathogenic missense mutations causing Mendelian human diseases
(from the Human Gene Mutation Database, HGMD).
Common SNPs and disease causing mutations were obtained previously for valida-
tion of POLYPHEN21. In our more stringent classiﬁcation of passenger mutations, we
discarded: 1) all passengers in genes that harbored more than one passenger, 2) pas-
sengers in any genes where ! >   (ﬁgure 5.2 on page 75), and 3) passengers that were
not ‘conﬁrmed’ somatic mutations in the COSMIC dataset (only 29.4% of mutations
in the database were ‘conﬁrmed’ by follow-up Sanger sequencing). Mean ∆PSIC for
this stringent set of passengers did not diﬀerent signiﬁcantly (p <  :  ) from our orig-
inal set, so it was not used for further controls as it greatly reduced sample size.
To stratify passengers into various subsets, we used several resources. 372 pas-
senger mutations were classiﬁed as ‘Homozygous’ by COSMIC, presumably due to
some kind of Loss of Heterozygosity event. ‘Housekeeping’ genes, were 195 genes with
passenger mutations and with one-to-one orthologs in S. cerevisiae, identiﬁed using
106InParanoid97. These genes are well expressed in humans, so we believe it is highly
likely that they are expressed in cancer. We could not directly normalize mutations
in our dataset by their expression levels because mutations in the COSMIC database
derive from varied literature sources (which often lack direct expression data). 881
non-COSMIC, non-synonymous passenger mutations were obtained from The Can-
cer Genome Atlas’ analysis of 38 Multiple Myeloma genomes22. This subset was used
as a control to ensure that any biases, which COSMIC might introduce via literature
curation, did not account for our observed scores.
A.1.1 A pan-cancer null model of mutagenesis
To parameterize our random model of pan-cancer mutations, we collected all 1,128
synonymous mutations present in COSMIC at the time of this study. Given our sam-
ple size, we parameterized our model to account for 3 types of point mutations: transver-
sions, CpG to TpG transitions, and all other transitions, as these 3 processes ex-
plained observed synonymous substitution patterns best (see below). Because some
genes in COSMIC, like KRAS or TP53, are sequenced more often than others, we
weighted both our estimated parameters and simulated mutations by the frequency
with which each gene was sequenced *. We weighted genes in this manner because the
frequency that genes were sequenced was highly variable and highly skewed, especially
towards driver genes.
The null frequency of each mutually-exclusive mutation type fi (CpG transitions,
*In the manifest of COSMIC, the curators note that they take care to record how often
a gene is sequenced, since it is critical to determining whether-or-not a gene is abnormally
mutated.
107other transitions, & transversions) was estimated as follows:
fi  
          ∑
j
wj
Oij
Pij
(A.1)
Here, Oij is the number of observed synonymous mutations in mutational class i,
for gene j, while Pij is the number of possible unique synonymous mutations for mu-
tational class i of gene j, and wj is the weight of gene j or fractional of cancer se-
quences reported in COSMIC belonging to gene j. This model explained the observed
patterns of nonsynonymous mutations with greater Bayesian information criterion
corrected log-likelihood than two-parameter models, as well as more sophisticated 10-
parameter models or models developed for human germ-line mutations114. Using this
model, random mutations were drawn with probability fiwj from the set of all pos-
sible genome-wide, nonsynonymous mutations. These randomly-generated mutations
were not only used as a null model for evolutionary conservation, but also as a neutral
null-model to test for signatures of positive and negative selection in cancer genomes
(ﬁgure 5.2 on page 75). Currently, there exist more sophisticated null-models of mu-
tagenesis that leverage more data and account for patterns in mutagenesis72.
A.2 Analysis of cancer genomes
To analyze mutations at a subtype-speciﬁc level (i.e. at the level of breast cancer,
lung cancer, etc), we leveraged the sequencing and classiﬁcations methods used in
the publication of each subtype’s genomic dataset. We felt that a systematic meta-
analysis was more appropriate at the subtype level, rather than pooling all data and
developing our own analysis pipeline (as we did above). Mutation calling and classi-
ﬁcations were done in the articles where the SNMs and SCNAs were ﬁrst identiﬁed
108in exome-sequenced tumor-normal pairs: breast115, colon21, lung28, and skin10 can-
cer (table 1.1 on page 4). MIN colorectal cancers were distinguished from non-MIN
tumors in a previous study21.
Driver genes for every subtype were identiﬁed using MutSig72 (for potential NSM
drivers) and GISTIC 2.086 (for potential SCNA drivers). To be deﬁned as a ‘driver’,
a mutation needed to arise in a gene with a Bonferroni-corrected enrichment p-value
          . All other mutations were classiﬁed as ‘passengers’.
We chose to normalize observed and expected distributions of mutation totals by
their median (for both our model and the neutral passenger model). This was done
because both models contain free parameters that arbitrarily alter their median. In
the neutral passenger model, this parameter is < n   
p >, while in our model, Tp=Td
and sp could be simultaneously adjusted to ﬁt the observed median without altering
other properties of the distribution (see equation (3.2) on page 34).
There were also 6 breast cancers (5% of the dataset) with mutation totals greater
than 4 times the median. All models in our study poorly explain these cancers, so
we excluded them from our analysis. The breast cancer distribution was then com-
pared to the various expected distributions using a violin plot. Error bar violin curves
denoting the bottom 5th and top 95th percentile of the observed distribution were
generated by creating 10,000 violin plots from 10,000 bootstrapped resamplings of the
observed distribution.
These analyses were repeated for the 11 cancer subtypes that currently have      
sequenced exomes. Using a Kolmogorov-Smirnov test for quality-of-ﬁt, we compared
each observed distribution to our simulated distributions for various sd   {0.05,
0.1, 0.2, 0.4, 0.6, 0.8} and identiﬁed the best-ﬁtting value of sd. We then repeated
these quality-of-ﬁt tests for the driver-only model and identiﬁed the values of k that
109best explain the observed distributions (ﬁgure 5.6 on page 82, table 5.1 on page 83).
In general, our model explains the observed distributions more accurately than the
driver-only model, with sd    :     : , while the driver-only model leads to unrealisti-
cally small values of k (between 1 and 2). In fact, for many caner subtypes, our model
explains the observed distribution to statistical resolution.
A.2.1 Inference of lesion formation rate
In the main text, we argue that r is at least 10 lesions   year   in breast epithelial.
This lower-bound estimate was based on the assumption that r  (     breast ep-
ithelial stem cells per mouse63)   (         human breast epithelial stem cells per
mouse breast epithelial stem cell)   (      initiating mutations per cell per year78)
    . Moreover, the number of lesions observed in normal breasts corroborates this
estimate98,123. Thus, we eliminate the possibility that age-incidence curves can be
explained by models which assume that most lesions eventually progress to cancer.
A.3 A traditional model of cancer progression with drivers and neu-
tral passengers.
In the traditional model of cancer progression used to estimate age-incidence curves,
it is assumed that a cancerous population transitions through k intermediate states
before malignancy:
C 
r1     C 
r2     :::
rk     Ck
Simply put, these intermediate states and transitions correspond to the many phe-
notypic changes that occur within a tumor as it progresses54. The instantaneous
110probabilities of each transition from one state to the next ri can vary in the general
case. Nevertheless, it has been shown that this predicts similar age-incidence rates to
a model where transition rates are all the same4. Thus, for parsimony we only con-
sider the case where all transition rates are the same constant r. Moreover, if the
transition rates are drastically diﬀerent from one another, then dynamics will largely
be determined by the slowest rate alone. The faster rates are then no longer ‘rate lim-
iting steps’ and can be neglected in timescale analysis.
From a genetic perspective, each transition corresponds to the acquisition of a new
driver in the population. However from a mathematical perspective, this model is
agnostic about the underlying molecular event that transitions a precancerous popu-
lation from one state to the next. Thus, this model can be expand to include any set
of heritable rate-limiting steps required for carcinogenesis: SNMs, SCNAs, alterations
in DNA and histone moieties, stable changes in cell signaling cascades, etc. Therefore,
we believe it is reasonable to assume that each rate-limiting step is the acquisition of
a new driver, as has been presumed for many years87.
We now consider the properties of this model when neutral passengers that do not
alter progression also accumulate. The precancerous population is now deﬁned by the
state Cnd;np. We consider the case where drivers accumulate at a ﬁxed rate rd and
111passengers accumulate at diﬀerent ﬁxed rate rp:
C ; 
rd     C ; 
rd     :::
  rp   rp
C ; 
rd     C ; 
rd     :::
  rp   rp
. . .
. . .
...
Cnd;np
As before, cancer arises once enough drivers accumulate (Cnd k;np).
To interpret age-incidence data, as well as genomics data, we are interested in both
the waiting time until cancer (t      ) and the total number of mutations (np   k).
This model can be simplify by noting that there is a freedom in the units for which
we measure time. In our simulations, time was measured in generations and then
converted to years. Here, we chose to measure time in units of the driver transition
probability rd and will then convert this to years afterwards. Hence, rd     with-
out loss of generality. Consider the quantity          t      rd, as a dimensionless
measure of the waiting time to cancer. It value will be roughly k on average. Because
driver and passenger accumulation events are independent processes in this model, the
joint probability of observing a cancer at time        with np passenger mutations,
P       ;np nd   k;rp , is:
P       ;np nd   k;rp    P        nd   k    P np       ;rp  (A.2)
This joint probability distribution provides a framework for identifying our quanti-
ties of interest.
112The waiting times to cancer in this neutral-passenger model, has been previously
shown to be a sum of exponentially-distributed waiting times4, i.e. an Erlang or Gamma
distribution, of the form:
P        nd   k    Erlang        nd   k;rd     
 
rk
dk 1
cancere rdcancer
 k    
  k  
      e cancer= k      
  tk  
       , when       =k ≪  
(A.3)
Traditionally in this model, it is believed that very few precancerous population
have enough time to progress, as lesion formation rates are much greater than can-
cer incidence rates. Hence, it is believed that age-incidence curves should be ﬁt with
only the beginning of this distribution: i.e. a power-law distribution (last line of equa-
tion (A.3)). We ﬁnd that although this hypothesis explains age-incidence rates well
at mid-age, it fails to explain the plateau in age-incidence rates seen at older ages in
most cancer subtypes (ﬁgure 5.3 on page 77, ﬁgure 5.4 on page 79).
In this model, the total number of passengers accumulated is a Poisson distribu-
tion, if the time of progression t       is known:
P np       ;rp    Poisson np  < np >  t      rp 
  e <np> < np >np =np 
(A.4)
Here, < np >  t      rp is the mean number of expected passengers. The distri-
bution takes this form because each passenger accumulation event occurs with an
exponentially-distributed waiting time; a Poisson distribution describes the sum of
events with exponentially-distributed waiting times in a ﬁxed time interval. Because
we do not know when a new lesion arrises, we must convolute this distribution with
113our expected distribution of t      .
The available time for cancer progression depends upon the length of a human life:
t     . If t      < t      , then the precancerous population will be unobserved in
age-incidence and genomics data because the person died of an alternate cause prior
to malignancy. Although the actual distribution of human lifetimes is complicated, we
can still make inferences about the validity of this model by considering its extremes.
Consider two opposing extreme cases: (1) when t      ≫ t      , all lesions eventually
progress and are sequenced (i.e. a human lifetime is much greater than the mean time
to cancer); and (2) when t      ≪ t      , only a few exceptional lesions progress (i.e.
the mean time to cancer is much shorter than a human lifetime). We ﬁnd that this
ﬁrst extreme predicts a much broader and more positively skewed distribution in the
number of passengers, than the second case. In either case, both distributions exhibit
similar predicted distributions in the number of total mutations. We used the second
extreme where a human lifetime is much shorter than the mean time to progression,
as this would be predicted by a power-law ﬁt to age-incidence curves.
In the case where t      ≫ t      , accumulation of passengers follows a binomial
process. Each accumulation event has probability p   rd= rd   rp  of being a driver
and probability      p  of being a passenger. Because the population has inﬁnite time
to progress to cancer, the binomial process continues until nd   k drivers accumulate.
A binomial process that continues until k successes (i.e. drivers), will have a total
number of failures (i.e. passengers) that samples a negative binomial distribution:
P np p;k   
(
np   k    
np
)
     p nppk (A.5)
A negative binomial distribution with p ≪   (i.e. passengers greatly outnumber
114drivers–as is the case in observed) reduces to a Poisson distribution.
In the case where t      ≪ t      , the waiting time to cancer follows a power law
distribution (equation (A.3) on page 113). This, convoluted with the distribution of
passengers expected for a particular t       (equation (A.4) on page 113) yields the
expected distribution of passengers for a cancer subtype:
P np k   
∫ h
  P        k P np       ;rp d      
 
∫ h
 
k 1
cancerk
k
h
e p
np
p
np  d      
   =  np  
∫ h
  e pk  
      
np
p d      
  k= k
hnp rk
p 
∫ p hrp
p   e p
k   np
p dp
 
(np k  
np
)
k < n   
p > k  k   np;< np >    
(A.6)
Where  s;x  is the normalized incomplete gamma function deﬁned previously
(equation (4.4) on page 48). In the above derivation, we eliminated a parameter by
considering the quantity: < np >     hrp, which corresponds to the mean num-
ber of passengers expected for a person who lives until the maximum allowable time,
h. Obviously, for both predicted passenger distributions (equation (A.6) and equa-
tion (A.5) on the previous page) the total number of mutations nd np is the expected
number of passengers P np k  plus the number of drivers k, which is constant.
A.4 Analysis of driver and passenger mutation covariates
To investigate possible alternate explanations for our observed correlation between
drivers and passengers we interrogated a wide-variety of alternative covariates in ta-
ble A.1 on the following page.
We observe a linear relationship between drivers and passengers that was predicted
115TableA.1: Linearrelationshipbetweendriversandpassengerscannotbeexplainedbyothertumorproperties.
Cancer Pearson’s r p-value* N  Spearman’s  slope  y-intercept
Drivers verses Passengers
breast 0.423 < 10 4 100 0.413 0.006 2.02
lung 0.368 0.08 24 0.998 0.005 8.63
colon, MIN  0.624 < 10 4 49 0.985 0.009 17.11
colon, MIN+ 0.916 < 10 5 14 0.999 0.047 6.50
melanoma 0.749 < 10 5 29 0.995 0.015 3.69
All 0.937 < 10 99 217 0.992 0.042 -3.81
SNM drivers versus SNM passengers
breast 0.390 < 10 4 100 0.178 0.005 1.34
lung 0.587 < 10 17 183 0.579 0.002 1.56
colon, MIN  0.990 < 10 134 159 0.569 0.054 2.65
colon, MIN+ 0.994 < 10 60 64 0.918 0.056 1.56
melanoma 0.878 < 10 9 29 0.974 0.012 2.59
All 0.924 < 10 223 536 0.592 0.050 -4.45
SCNA drivers verses SCNA passengers
breast 0.443 < 10 5 100 0.433 0.024 0.17
lung 0.253 0.23 24 0.998 0.028 5.94
colon, MIN  0.770 < 10 9 49 0.984 0.008 9.44
colon, MIN+ 0.424 0.13 14 0.994 0.029 6.01
melanoma 0.559 < 10 10 121 0.663 0.023 5.23
All 0.573 < 10 27 309 0.962 0.012 5.76
SNMs versus SCNAs
breast 0.052 0.61 100 0.149 0.237 64
lung 0.169 0.43 24 -0.548 1.268 334
colon, MIN  -0.080 0.58 49 -0.068 -0.021 137
colon, MIN+ -0.265 0.36 14 0.045 -0.981 838
melanoma -0.114 0.56 29 0.176 -0.183 431
All 0.331 < 10 6 217 -0.089 0.631 133
Drivers verses Pathological Grade
breast 0.163 0.10 100 0.113 0.067 2.25
lung -0.048 0.83 22 0.024 0.006 2.13
colon, MIN  -0.187 0.20 48 0.072 0.012 2.67
colon, MIN+ -0.121 0.68 14 -0.338 0.004 3.09
melanoma 0.221 0.35 20 0.120 0.025 1.83
All 0.018 0.80 204 0.054 0.001 2.37
SNMs versus Pathological Grade
breast 0.217 0.03 100 0.444 0.001 2.33
lung 0.193 0.02 158 0.235 0.000 1.79
colon, MIN  -0.084 0.30 156 0.039 0.000 2.51
colon, MIN+ -0.045 0.73 63 -0.023 0.000 2.50
melanoma 0.119 0.62 20 0.114 0.000 2.06
All -0.012 0.80 497 0.147 0.000 2.28
SCNAs versus Pathological Grade
breast 0.248 0.01 100 0.235 0.007 2.18
lung 0.170 0.45 22 0.026 0.002 1.85
colon, MIN  -0.166 0.26 48 0.081 0.000 2.48
colon, MIN+ -0.054 0.85 14 -0.333 0.000 2.99
melanoma 0.109 0.31 88 -0.253 0.000 2.06
All -0.067 0.27 272 -0.112 0.000 2.38
Negative values are in gray.
*Statistically signiﬁcant (p <  :  ) relationship are in bold
  Number of samples compared
  Denotes sp=sd when comparing drivers to passengers
116by our model. Above the thick black line are relationships that appear to robustly
covary, while the bottom half contains relationships that we believe are insigniﬁcant.
In our model, driver’s and passenger’s linear relationship results from their compet-
ing eﬀect: additional deleterious passengers must be overcome by additional drivers.
However, this relationship could conceivably be explained by alternate factors; in par-
ticular, we were concerned that the mutation type, mutation rate, or aggressiveness of
the tumor could also explain the observed relationship. The data above suggest that
these possibilities are unlikely, thus supporting our conclusion that drivers compete
with passengers.
Our rational for the above competing hypotheses and why we reject them are as
follows:
1. SCNAs and SNMs might have drastically diﬀerent eﬀects on cancer progres-
sion and undermine our model. The slope and y-intercept between drivers and
passengers is approximately equal in SCNAs and SNMs, suggesting the relative
ﬁtness eﬀects of these mutations is similar.
2. Some cancers might progress via CIN, while others progress via an elevated
point mutation rate. If so, a negative correlation between SCNAs and SNMs
within tumor subtypes would be expected, which has been observed previously
in a pan-cancer study23 and within the aggregate colorectal dataset. However,
this does not appear to be so in other tumor types, nor in colorectal cancer af-
ter segregation according to MIN phenotype. Thus, the observed patterns are
not explicable by varying mutational mechanisms.
3. The relationship between drivers and passengers might be a result of variation
in mutation rate. Variation in the mutation rate should only alter the wait-
117ing time to cancer in the neutral-passenger model, and not alter mutation to-
tals. Nevertheless, if variation in the mutation rate could explain the correla-
tion between drivers and passengers, then stratifying tumors by their mutation
rate should reduce the correlation. Because the relationship between drivers
and passengers is persistent and strong within the MIN  and MIN subtypes—
expected to have and not-have a mutator phenotype—we reject this hypothesis.
4. Tumors with more drivers and passengers might simply be more evolutionarily
advance. Suppose some cancers are detected and sequenced later than others.
These late cancers would not only possess additional drivers, but also additional
passengers, even if passengers were neutral; thus, retaining the correlation be-
tween drivers and passengers. However, late-detected tumors with additional
drivers should also be more advanced and more aggressive. We ﬁnd that a tu-
mor’s pathological grade is uncorrelated with the number of drivers, refuting
this possibility. Pathological grade was quantiﬁed by converting roman numer-
als into a linear scale (i.e. A Stage IV tumor corresponds to an aggressiveness
of 4). Many tumors had intermediate grades that were given corresponding
fractional values (e.g. a Stage IIIa tumor was translated into a 3.0, a Stage IIIb
was given 3.3, and a Stage IIIc was given 3.7). Because this quantiﬁcation of
tumor grade may distort the scale of aggressiveness, Spearman’s Rank correla-
tions are provided.
For completeness, the relationship between SNMs and Pathological Grade,& SCNAs
and Pathological Grade are also shown.
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